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CHAPTER I 
 
INTRODUCTION 
 
RAGE: A Multiligand Receptor for Advanced Glycation End Products 
 RAGE is a cell surface receptor initially discovered and named for its ability to 
bind proteins modified by glucose metabolites termed advanced glycation end products 
(AGEs) (1, 2). AGE signaling through RAGE is widely thought to play a role in the 
progression of diabetic complications and chronic inflammatory processes (3). In the past 
15 years, RAGE has been shown to interact with a range of structurally and functionally 
diverse ligands including AGEs, amphoterin, amyloid-β peptides, and members of the 
S100 protein superfamily (4). Interaction with these ligands implicates RAGE in several 
physiological processes (neural growth, acute inflammation) and disease pathologies 
(diabetes, tumor growth/metastasis, Alzheimer’s disease, chronic inflammation) 
implicating RAGE as a promising lead for therapeutic intervention (4, 5). 
 RAGE is a member of the immunoglobulin (Ig) superfamily with three predicted 
Ig-like domains in its N-terminal extracellular region, in addition to a single 
transmembrane helix and small intracellular domain (Figure 1.1). The extracellular Ig-
like domains have been classified as an N-terminal V-type domain and two subsequent 
C-type domains (1). However, no direct structural data existed prior to the work in this 
dissertation to confirm or refute this assignment, specify RAGE quaternary structure, 
elucidate the basis for interactions with structurally diverse ligands, or generate 
hypotheses about receptor autoinhibition and activation. The issue of sRAGE quaternary 
1 
is important for understanding how an initial binding event causes a signal to be 
transferred across the cell membrane. The basis for interactions with structurally diverse 
ligands is critical when addressing the issue of pharmaceutical intervention. And lastly, 
addressing both of these issues can provide insight into mechanisms of receptor 
autoinhibition and activation. Thus, the desire to obtain a broader knowledge of how 
RAGE functions in the cell and malfunctions in disease set the stage for the structural, 
biochemical, and biophysical work presented in this dissertation. 
 
 
Figure 1.1: Schematic of RAGE domain organization. The membrane is shown as a 
horizontal rectangle with the extracellular and intracellular regions marked appropriately. 
The intracellular domain (IC) is shown as a random black sketch. The single 
transmembrane helix (TM) is a black vertical rectangle. The three predicted Ig-like 
domains of sRAGE are shown above the membrane. The predicted C-type Ig domains are 
depicted in dark blue (C1) and violet (C2). The predicted V-type Ig domain is shown in 
red. 
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RAGE Biology 
 In this section, I describe the current knowledge of RAGE function associated 
with normal physiology and cellular dysfunction. There is a wealth of information on the 
biology associated with RAGE as a signaling receptor. One fascinating aspect of RAGE 
biology is its recognition of structurally diverse ligands, which can be grouped into four 
classes: (1) AGEs, (2) amphoterin, (3) amyloid-β peptides (Aβ), and (4) S100 proteins. 
While multiligand recognition is not directly addressed, the conclusions and future 
directions in this dissertation are discussed with respect to signaling mechanisms 
specifically implicated by multiligand recognition. For scientific completeness, I also 
delve into the diverse biology associated with these ligands and some of their non-RAGE 
functions. 
 
Advanced Glycation End Products (AGEs) 
AGE Chemistry 
 Protein glycation is a non-enzymatic process initially discovered by Louis 
Maillard who observed chemical modifications to amino acids when heated in the 
presence of reducing sugars, a process often referred to as the Maillard reaction. During 
the early stages of glycation, sugars such as glucose form a Schiff base with free amino 
groups on proteins at the N-terminus or on lysine and arginine side chains (Figure 1.2) 
(6). The Schiff base undergoes a rearrangement involving proton transfer to the more 
stable and reversible Amadori Product (Figure 1.2). The late stages of glycation are 
irreversible and consist of a variety of chemical modifications. The best studied AGE 
moiety is N(epsilon)-(carboxymethyl)lysine (CML) which results in a charge reversal 
3 
(Figure 1.2) that could disrupt intra- or intermolecular salt bridges. Overall, the 
consequences of AGE formation can be as diverse as their chemistry. 
 
 
Figure 1.2: Chemical pathway towards AGE formation. In the first reversible step, D-
glucose reacts with free amino groups on a protein forming a Schiff base (circle with 
letter “P” represents the protein). Reversible proton transfer leads to Amadori product 
formation in the second step. Finally, a series of irreversible non-enzymatic chemical 
reactions leads to AGE-modified protein (example shows CML modification to lysine 
side chain). Figure adapted from (6). 
 
AGEs in Normal Aging and Diabetes 
 The accumulation of advanced glycation end products is dependent on two 
primary factors, the concentration of aldose sugars such as glucose and the half-life of the 
modified protein. Prolonged hyperglycemia associated with diabetes increases the 
concentration of glucose, a precursor to many AGEs. Observations in the late 1980s 
suggested AGEs played a role in the pathogenesis of cardiovascular disorders (7). These 
authors took advantage of the yellow-brown fluorescent pigmentation with characteristic 
UV absorption of AGEs. They compared the levels of an Amadori product to those of the 
highly fluorescent advanced glycation end product in rat aorta. Amadori product levels 
reached a maximum between 50 and 70 weeks whereas levels of the fluorescent 
advanced product reached maximum levels between 90 and 120 weeks old (7). This 
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observation implied a correlation between AGE formation and age. A similar study on 
humans showed increased Amadori levels between Type 1 diabetic patients versus 
control patients, but no correlation between duration or severity of diabetes (8). However, 
there was a direct correlation between the duration and severity of diabetic complications 
and the levels of fluorescent protein adducts, assumed to be AGEs as a result of 
prolonged hyperglycemia (9). Thus, it appeared that the irreversible AGE moieties and 
not the reversible Amadori products were associated with diabetes. 
 AGE formation has been directly observed on cellular components associated 
with complications of diabetes. Human cataract eye lens show characteristics of AGE 
formation compared to lens from non-cataract patients (10). Similar observations were 
made on insoluble fractions of collagen comparing both old to young patients and normal 
patients to those age-matched with Type 1 diabetes (11, 12). Additional work correlates 
AGE-β2 microglobulin in patients on long-term hemodialysis suggesting AGE-related 
pathogenesis in patients being treated for renal failure (13). Lastly, in vitro formation of 
amyloid-β peptide (Aβ) aggregates, a major component of senile plaques, occurs rather 
slowly but is markedly enhanced when seeded with AGE-modified Aβ suggesting AGE 
modification may be a catalyst for aggregate formation in Alzheimer’s brain (14). In a 
similar example, antibodies positively stain two AGEs, pentosidine and pyrraline, on 
senile plaques and neurofibrillary tangles (15). Thus, the high insolubility and resistance 
to denaturant of neurofibrillary tangles could be a byproduct of AGE induced covalent 
aggregation (16). 
 Initial work to discover potential receptors for AGEs characterized a 90 kDa 
protein from murine macrophages that bound a synthetic AGE compound with 
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nanomolar affinity (17, 18). Concurrent with work on macrophages were experiments on 
endothelium, tissue that lines the interior of blood vessels and whose dysfunction is 
connected with diabetic vascular complications. AGE-bovine serum albumin (AGE-
BSA) specifically binds to cultured endothelial cells (19). Interestingly, monolayers of 
endothelial cells show increased vascular permeability, in addition to modulated 
coagulant properties, when in contact with AGE-BSA (19). Thus, the aggregate evidence 
suggests AGEs accumulate in long-lived proteins such as collagen and their localization 
leads to interaction with cell surface molecules causing cellular dysfunction. Studies of 
these diverse aspects of AGE biology lead to the search for and eventual discovery, 
isolation, cloning, and characterization of RAGE. 
AGE Signaling Induces Oxidative Stress Though RAGE 
 The progression of diabetic hyperglycemia to cardiovascular disease, renal 
failure, etc. may arise from tissue damage or altered signaling pathways caused by 
increased oxidative stress in cells. Cultured capillary endothelial cells (a cell type present 
in the vasculature that is damaged in diabetes) show increased oxidative stress in 
response to treatment with AGE-BSA, which was blocked by antibodies to RAGE (20). 
In addition, electrophoretic mobility shift assays show AGE-BSA binding to RAGE 
induces specific translocation of nuclear factor kappa-B (NF-κB) to the nucleus (20). NF-
κB is a well characterized transcription factor best studied for its role in gene expression 
in response to inflammatory stimuli in the immune system (21). In fact, oxidative stress 
alone in the form of hydrogen peroxide and superoxide radical induces NF-κB activation 
on T cells (22). Therefore one possible interpretation of the data is that AGE-BSA 
interacts with RAGE leading to increased oxidative stress which in turn induces 
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activation of NF-κB by a secondary mechanism. Another possibility is that AGE-BSA 
binding to RAGE directly leads to activation of signaling pathways causing oxidative 
stress on the target cell. Subsequent work has confirmed that activation of signaling 
pathways, and not binding alone, is necessary thereby establishing RAGE as a signaling 
receptor (23). 
Signaling Pathways Triggered by AGEs 
 Many of the kinases involved in signaling between ligand binding and NF-κB 
activation have also been identified. In pulmonary artery smooth muscle cells treated 
with AGE-BSA, activation of NF-κB occurs through p21ras and the extracellular signal 
regulated kinase 1/2 (ERK1/2) (24). In human monocyte cells, both ERK and p38 
mitogen activated protein kinase (MAPK) were activated by CML modified human 
serum albumin (HSA) (25). This study also showed no activation of the third kinase 
family, janus kinase. Thus, RAGE signaling in response to AGE exposure is a link to cell 
stress associated with diabetic vascular complications and stimulated interest in 
understanding RAGE biology. 
 
RAGE Activation by Amphoterin: a Physiological Role for RAGE 
 Analysis of RAGE tissue distribution shows higher protein expression in 
developing tissue than in adult tissue (26). This observation suggests endogenous ligands 
may be present to activate RAGE during development. Amphoterin was identified as the 
first “natural” ligand for RAGE (AGE formation being an “unnatural” ligand due to the 
non-enzymatic chemistry). In situ hybridization and immunohistochemistry showed high 
expression and colocalization of RAGE and amphoterin in developing cerebral cortex, 
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hippocampus, and cerebellum of rat brains (27). In vitro, amphoterin binds to RAGE with 
the highest affinity of all ligands (KD = 6.4 nM) and induces neurite outgrowth on 
cultured neurons (27). Receptor-dependent neurite outgrowth, therefore, was the first 
established native function for RAGE in the cell. 
 Amphoterin is one of several diffusible factors that induce neurite outgrowth on 
cultured neurons, a function vitally important during nervous system development (28, 
29). Prior to its discovery as a neurite outgrowth factor described above involving RAGE, 
amphoterin (high mobility group 1, HMG1) had been characterized for its DNA binding 
activity and association with chromatin as a non-histone component (30, 31). In addition 
to DNA binding activity, HMG1 interacts with DNA-binding proteins and may modulate 
DNA processing events such as transcription (32, 33). 
 Amphoterin is described as containing two ~10 kDa HMG box motifs identified 
by sequence homology and shown to be structurally independent by limited proteolysis 
(34, 35). In addition, a highly acidic C-terminal extension exists adjacent to the two 
structured domains (34). Solution structures are available for each of the two HMG box 
motifs of rat amphoterin (Figure 1.3). The two domains are highly homologous with 
backbone RMSD of 2.0 Å (36, 37). The fold is predominately α-helical with helices 1 
and 2 forming an approximate right angle with respect with helix 3 (Figure 1.3). This L-
shaped α-helical structure is quite different from the small chemical modifications that 
make up AGEs. In addition, the name amphoterin is derived from the primary sequence 
showing two regions with completely different electrostatic properties; both HMG box 
domains are quite basic while the C-terminal extension is quite acidic. In fact, it appears 
that the basic region (pI ~10.0), part of which is α-helical in the HMG box B structure 
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(Figure 1.3), is capable of binding to RAGE (38). Thus, it is possible that molecules with 
different electrostatic properties are recognized by RAGE. 
 
 
Figure 1.3: Structure of rat amphoterin. Ribbon diagrams representing one model of 
solution structures of the two HMG box domains of rat amphoterin (rat and human are 
>99% identical). The N-terminal “A” domain corresponding to residues 1-83 of native 
amphoterin (PDB 1AAB) is shown in green. The C-terminal “B” domain corresponding 
to residues 88-164 of native amphoterin (PDB 1HME) is shown in blue. N- and C-termini 
of each domain are marked accordingly. A portion of the amphoterin peptide known to 
bind and antagonize RAGE is colored in pink. The remainder of this peptide was not 
included in the construct used in structure determination. All protein structure images in 
this dissertation were made using Chimera (39). 
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RAGE Binding to Amyloid β: Implications in Neurotoxicity 
 Alzheimer’s disease (AD) is a progressive neurodegenerative disorder 
characterized by lesions in regions of the brain important for intelligence and memory. 
Two primary morphologies are observed, neurofibrillary tangles and senile plaques. The 
major protein component of neurofibrillary tangles are tau protein aggregates while that 
for senile plaques are amyloid fibrils composed largely of amyloid β (Aβ) peptides from 
the amyloid precursor protein (APP). RAGE has been identified as a protein capable of 
binding Aβ peptides and does so with low nanomolar affinity (40). 
 APP is an integral membrane protein with a large extracellular domain, a single 
transmembrane helix, and a small intracellular domain. Normal cellular processing of 
APP in lysozomal compartments leads to proteolytic fragments that are secreted from 
various cells in culture (41). However, neither the function of APP nor the role of normal 
protein turnover is well understood. In senile plaques, Aβ peptides are heterogeneous in 
length but average around 40 amino acids. Nonetheless, isolated Aβ peptides offer 
functional and structural features unique from AGEs and amphoterin. 
 The interaction of soluble Aβ peptide with RAGE induces migration of microglial 
cells and oxidative stress in endothelial cells, both of which are RAGE dependent (40). 
Thus, RAGE may enhance neurotoxicity directly through Aβ peptide interaction or 
indirectly by inducing microglial infiltration. The role of RAGE as a signaling receptor in 
neurodegenerative disorders was strengthened by studying a transgenic mouse model for 
AD expressing a mutant form of APP (42). Transgenic mice also expressing a signaling 
deficient form of RAGE (dnRAGE, see below) show markers such as enhanced NF-κB 
activation and diminished learning and memory compared to mice only expressing wild-
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type RAGE, consistent with its role as a signaling receptor in Aβ induced neuropathy 
(42). 
 
S100 Proteins are RAGE Ligands 
 The continued search for native ligands of RAGE lead to the identification of a 
gene termed EN-RAGE (endogenous RAGE) (43). Analysis of the sequence revealed 
EN-RAGE was a member of the S100 superfamily of EF-hand proteins, S100A12. The 
precise function of S100 proteins is not well understood. Nonetheless, they are involved 
in diverse biological processes. 
 S100A12 (EN-RAGE) is one of the calgranulins, which are exclusively expressed 
and secreted from granulocytes of the immune system. Radioligand binding assays show 
S100A12 binds with KD ~90 nM to both purified RAGE and RAGE on the endothelial 
cell surface (43). RAGE activation by S100A12 on endothelial cells induces nuclear 
translocation of NF-κB and the subsequent expression of vascular cell adhesion 
molecule-1 and intercellular adhesion molecule-1, both mediators of the inflammatory 
response. Furthermore, S100A12 clearly promotes cell migration of mononuclear 
phagocytes in a chemotaxis assay strongly suggesting a RAGE-S100 protein role in acute 
inflammation (43). 
 A second S100 protein, S100B, was shown to activate RAGE (44). S100B is 
known to regulate the extension of neurites in vitro (45, 46). At nanomolar concentrations 
of S100B, neurite outgrowth is promoted. This function appears to be coregulated in an 
additive manner by S100B, S100A1 and amphoterin up to 1 µM. At micromolar 
concentrations, however, both S100 proteins lead to cellular toxicity and apoptosis 
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through the caspase cascade (44). For all three proteins at neurotrophic concentrations, 
RAGE activation led to NF-κB upregulation (44). 
 S100A12 and S100B are the best studied RAGE ligands in the S100 superfamily. 
However, other S100 proteins are implicated in RAGE biology. S100P is overexpressed 
in many cancers. In both NIH3T3 and pancreatic cancer cells, S100P is 
coimmunoprecipitated with RAGE and activation of NF-κB is blocked with a signaling 
deficient RAGE (dnRAGE, see below) (47, 48). S100A4 leads to RAGE dependent 
activation of p38 MAPK, nuclear translocation of NF-κB, and overproduction of matrix 
metalloprotease 13 in cultured human chondrocytes (49). And lastly, S100A11, 
overexpressed in osteoarthritic cartilage, appears to activate chondrocytes by signaling 
through RAGE and p38 MAPK (50). S100 protein activation of RAGE is likely regulated 
by the subcellular localization and tissue-specific nature of S100 proteins since many in 
the superfamily bind to and activate RAGE. 
 S100s are small, acidic, α-helical proteins with high structural similarity across 
the family. A ribbon diagram of human S100B is shown in Figure 1.4. While S100 
proteins share secondary structure elements with amphoterin, there is no shared tertiary 
structure nor is there any similarity to AGEs or Aβ. In addition, S100 proteins can be 
quite acidic with S100B having an isoelectric point of 4.6. The biochemistry of S100B as 
a RAGE ligand is studied in this dissertation. Therefore, a more detailed discussion of 
S100 protein structure is warranted and included in the next section. 
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 Figure 1.4: Solution structure of Ca2+-loaded human S100B. The ribbon diagram (PDB 
1UWO) shows one subunit of the symmetric homodimer in red and the other in orange. 
All S100 protein structures in this dissertation are shown in this orientation with the two 
HIV helices in front and the two HI helices in back. 
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Divergent Signaling Pathways and Essential Signaling Elements 
Kinase Pathways 
 AGE binding to RAGE induces the activation of NF-κB through p21ras and 
ERK1/2. Much like AGEs, amphoterin induces the translocation of NF-κB to the nucleus 
in cultured neuroblastoma cells (23). However, rac and Cdc42 were used to signal to NF-
κB instead of ras and ERK1/2. Working in a fibrosarcoma cell line (HT1080), Ishihara 
and coworkers showed amphoterin activates ERK1/2 (51). This cell line is more similar 
to the endothelial cells used in AGE studies than the neural cells used by Huttunen and 
coworkers. Thus, it is possible that the signaling pathways used by RAGE are cell type 
dependent but not ligand dependent. Interestingly, ERK1/2 coimmunoprecipitated with 
RAGE from HT1080 cells after activation with amphoterin. The interaction with ERK2 
(ERK1 was not tested) was specifically localized to the first 18 amino acids of the 
intracellular domain in glutathione S-transferase (GST) pull downs from rat lung extracts 
(51). 
Dominant-Negative RAGE 
 A very important observation was made during initial studies with amphoterin. A 
truncation mutant of RAGE was transfected into neuroblastoma cells that had 
endogenous expression of RAGE. This truncation mutant lacked the ~40 amino acid 
intracellular domain (IC). Translocation to the membrane was not prevented nor was 
amphoterin or AGE-BSA binding. Cell signaling, however, was deficient in the construct 
lacking the IC (23). Since wild-type RAGE is also present at the cell surface and ligand 
binding is not diminished, a dominant-negative form of RAGE (dnRAGE) implies that 
RAGE functions in some sort of oligomeric state. The likely role of RAGE in neural 
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growth and development and in progression of diabetes and chronic inflammatory 
disorders, coupled with utilization of divergent signaling pathways described in this 
section, has greatly stimulated interest in RAGE as a signaling molecule. 
Positive Feedback Loop 
 Additional insights into RAGE signaling arose from analysis of its promoter. Two 
functional NF-κB-like binding sites have been characterized, both of which are necessary 
for basal RAGE expression and increased RAGE expression in response to stimuli (52). 
RAGE expression is shown to increase in diabetic versus normal vasculature, as well as 
other pathologic settings (53). Therefore, an interesting scenario has arisen in RAGE 
biology. Binding of ligand to RAGE activates NF-κB which in turn enhances RAGE 
expression increasing potential cell surface binding sites. This positive feedback loop has 
been hypothesized to be responsible for the RAGE induced amplification of chronic 
disorders such as diabetes and inflammation (54). 
 
Potential for RAGE-Based Therapeutics 
 As described above, RAGE participates in a diverse array of biological and 
pathological processes each defined by the particular class of ligand activating the 
receptor. Due to its implied role in multiple disease states, RAGE is considered a 
therapeutic target (55). In fact, ligand binding in a variety of culture systems leads to 
activation of signaling pathways consistent with the associated disease states (5). This 
suggests blockade of the RAGE signaling axis could provide an avenue for 
pharmaceutical intervention. Exogenous sRAGE has been used to block ligand binding 
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and to prevent receptor activation in cell culture. These observations have been translated 
into mouse models for various diseases. 
Diabetes
 Apolipoprotein E-null mice naturally develop accelerated atherosclerosis and 
show a greater than 2 fold increase in plasma AGEs (56). Intraperitoneal administration 
of sRAGE significantly blocked the development of atherosclerotic lesions in the aorta 
(57). The mechanism is presumably through blockade of AGE-RAGE interaction since 
neither hyperglycemia nor insulinemia were affected. 
Cancer
 Transplanting C6 glioma cells into immunocompromised mice causes rapid tumor 
growth that is significantly suppressed by intraperitoneal administration of either sRAGE 
or antibodies against RAGE or amphoterin (58). Furthermore, stably transfected C6 
glioma cells either expressing dnRAGE or secreting sRAGE showed neither tumor 
growth nor tumor metastasis. Thus, the leading edge colocalization of amphoterin and 
RAGE observed in culture (27) implies a mechanism for promoting (and blocking) tumor 
invasion. 
 In a similar study, B16-F1 melanoma cells were injected into the tail veins of 
immunocompromised mice and assessed for colonies indicative of lung metastasis (38). 
Two strategies suggested an amphoterin-RAGE signaling axis is important for formation 
of metastatic colonies in the lung. One, injecting cells transfected with dnRAGE showed 
72% fewer colonies than injection of parental B16-F1 cells (38). The second involved 
coinjection of B16-F1 cells with an amphoterin peptide antagonist (amphoterin 150-183), 
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which caused a 64% reduction in lung metastatic colonies (38). Thus, multiple lines of 
evidence point to an amphoterin-RAGE axis important in tumor metastasis. 
Alzheimer’s Disease
 The vascular theory of AD states that accumulation of Aβ in Alzheimer’s brain 
may arise from circulating Aβ and dysfunction of the equilibrium of peptides across the 
blood brain barrier (BBB) (59). BBB transport would presumably require specific cell 
surface receptors for Aβ. Using an in vitro model for BBB, anti-RAGE antibodies 
prevented transport of peptides suggesting a role for RAGE (60). Transgenic mice 
expressing mutant APP function as a model for AD since Aβ containing plaques 
accumulate rapidly in the brain and correlate with impaired learning and memory (61). 
Treatment with sRAGE results in high levels of sRAGE-Aβ coimmunoprecipitates from 
plasma in addition to decreased levels of Aβ plaque formation (62). 
Chronic Inflammation
 Another potential therapeutic approach is based on the interaction of RAGE with 
S100A12 which is highly associated with chronic inflammation such as inflammatory 
bowel disease. Interleukin-10 deficient mice serve as a model for enterocolitis 
characterized by hyperactive bowel inflammation (63). In this model, administration of 
sRAGE prevented inflammatory infiltrates into the colon likely by blocking S100-RAGE 
interaction and signaling (43). 
 
Concluding Remarks 
 There is a wealth of information on the biology associated with RAGE as a 
signaling receptor. Comparing the signaling pathways utilized by all ligands suggests that 
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RAGE universally signals through NF-κB. The biological processes involved range from 
neural growth and development and acute inflammatory responses to complications 
associated with diabetes and AD. Thus, knowledge gained by studying one aspect of 
RAGE function has the potential to transcend all aspects of RAGE biology. 
 
S100 EF-Hand Calcium-Binding Proteins 
 S100 proteins, specifically S100B, are a major focus of this dissertation. These 
proteins have been well characterized structurally and biochemically (64) and reagents 
were readily available to pursue structural studies on S100-RAGE interaction. In this 
section I take a broader look at calcium signaling involving S100 proteins in addition to 
the current knowledge about S100 protein structure and function. 
 
Structure of the EF-hand Motif 
 The calcium ion is known to function as a second messenger in many signaling 
cascades. Signal transduction from a physiological change in calcium concentration to a 
biochemical response in the cell is mediated by EF-hand calcium-binding proteins. The 
EF-hand is a helix-loop-helix motif in which the protein chelates calcium ions using a 
series of side chain and backbone oxygen atoms (65). The prototypical EF-hand protein is 
calmodulin, a single polypeptide with four EF-hand motifs organized into two structural 
domains separated by a flexible linker. Each domain consists of paired EF-hand motifs 
that fold into a stable four helix bundle. Each EF-hand is able to bind one ion of calcium. 
Thus, calmodulin binds four calcium ions, two in each structural domain. 
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Calcium Sensing by EF-Hand Proteins 
 The functional role of EF-hand proteins in calcium signal transduction is 
mediated by structural and biophysical responses to changes in intracellular calcium 
concentration (66). The prototypical EF-hand calcium sensor, calmodulin, binds calcium 
ions with KDs of ~10-6 and ~10-5 for the C- and N-domains, respectively, in the range of 
the intracellular calcium signal (67). Thus, at basal levels of calcium, calmodulin is in a 
magnesium-bound or the apo- (calcium-free) state. The release of calcium from 
intracellular stores during response to a stimulus leads to micromolar concentrations of 
calcium, with possible subcellular compartments exposed to millimolar concentrations. 
At mid-micromolar or higher concentrations of calcium, all four binding sites are filled 
and calmodulin is activated. The structural basis for calmodulin signaling activity is 
revealed by comparative analyses of apo- and calcium-bound structures. Upon binding 
calcium, both domains of calmodulin undergo large structural rearrangements exposing 
deep hydrophobic pockets frequently used to bind to α-helical target peptides (66). 
 
Architecture of the S100 Protein 
 S100 proteins are EF-hand containing calcium binding proteins named for 
solubility in 100% saturated ammonium sulfate. The architecture of an S100 protein is 
quite different from calmodulin. The minimal structural and functional S100 unit is a 
highly integrated symmetric homodimer first seen in the structure of S100A6 (calcyclin) 
determined in our laboratory (68). Each subunit of the S100 dimer consists of two EF-
hands connected by a hinge region similar to each of the domains of calmodulin. The C-
terminal EF-hand motif is canonical (calmodulin-like) whereas the N-terminal EF-hand is 
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S100-specific (69). Unlike the canonical 12 residue EF-hand, the S100-specific EF-hand 
is 14 residues and displays weaker affinity for calcium. Much like calmodulin, affinities 
for calcium are in the range of the intracellular calcium signal classifying most S100 
proteins as calcium sensors. 
 Calcium binding to S100 proteins induces a similar yet different conformational 
change than calcium binding to calmodulin for two reasons. One, helices HI and HIV form 
the tightly integrated dimer interface and are therefore restricted. Two, the S100-specific 
EF-hand resembles the calcium bound state even when calcium is absent (70, 71). It has 
been proposed that the S100-specific EF-hand is stabilized in the absence of calcium by 
the presence of a water molecule in the binding site. Such a water molecule showing 
similarity to the calcium coordination geometry was observed in the S100-specific 
binding loop of apo-S100A3 (72). Regardless of the origin of the effect, the major 
conformational change in S100 proteins occurs in the C-terminal EF-hand, specifically in 
helix HIII (Figure 1.5). Calcium binding to S100 proteins creates a shallow hydrophobic 
surface much different from the deep hydrophobic pocket formed by calcium binding to 
calmodulin. 
 Due to the high sequence homology among the S100 protein family, it is not 
surprising that they adopt similar structures in both the absence and presence of calcium 
(73). However, many subtleties exist. For example, S100A7 and S100A10 have amino 
acid substitutions or deletions that inactivate calcium binding at key glutamate/aspartate 
residues in the EF-hands (74). Remarkably, an x-ray crystal structure of S100A10 bound 
to a target peptide reveals that calcium is not required to stabilize the open conformation 
since it is sufficiently stabilized by the binding of target (75). It has yet to be determined 
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whether S100A10 adopts the calcium-bound state in the absence of target binding or is in 
dynamic exchange between the apo- and calcium-bound states. 
 
Figure 1.5: Calcium induced conformational change in S100A6. Solution structures of 
apo-S100A6 (left, PDB 1CNP) and Ca2+-loaded S100A6 (right, PDB 1A03). For each 
homodimer, one subunit is shown as a light blue Cα trace with a dark blue ribbon 
diagram showing the 4 helix bundle. The two molecules have been aligned by helices HI 
and HIV at the dimer interface. Colored in pink is helix HIII emphasizing the calcium 
induced structural change. 
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S100 Proteins and Zinc 
 S100 proteins exhibit the ability to bind other metals, a characteristic that 
distinguishes them among EF-hand proteins. For example, S100A2 has at least two high 
affinity sites for zinc (II) that are independent from the calcium binding sites (76). 
Binding to zinc (II) occurs with nanomolar KDs, near the physiological levels of 
intracellular zinc (II). A solution structure of S100B bound to zinc (II) reveals utilization 
of sites separate from the calcium binding sites (77). Unlike calcium binding which 
induces a large conformational change in helix HIII, binding of zinc (II) to S100B causes 
very little structural perturbation (77). 
 The S100A8/S100A9 heterodimer has also been characterized as a zinc (II) 
binding protein (78). S100A8/S100A9 is highly expressed in monocytic cells of the 
immune system and is thought to play a role in the hummoral response to pathogen 
invasion (79). Addition of the heterodimer but not the individual homodimers inhibits 
growth of cultured Candida albicans (80). Furthermore, growth inhibition by the 
S100A8/S100A9 heterodimer is reversed by addition of excess zinc (II). Thus, the 
antimicrobial activity of the S100A8/S100A9 heterodimer may occur through chelation 
of essential zinc (II). A newly described human disorder characterized by aberrant zinc 
metabolism, called hyperzincaemia, is correlated with highly elevated levels of 
S100A8/S100A9 heterodimer (81). 
 
Higher Order Oligomeric States of S100 Proteins 
 Although S100 proteins form highly integrated dimers, evidence has been 
gathering in support of S100 proteins functioning in vivo as higher order oligomers. Early 
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reports on the neurotrophic effects of S100B suggested disulfide-linked higher order 
oligomeric species were essential for function (45, 46, 82). More recent evidence arises 
primarily from crystal structures and other biophysical techniques. S100A12 has been 
crystallized in numerous forms, including a hexameric structure (83, 84). This hexamer 
was apparently stabilized by additional calcium binding sites between individual dimers 
(85). There is some biophysical support for higher order oligomer formation in the 
absence of lattice forces from crystal packing. Dynamic light scattering (DLS) reveals an 
increase in the hydrodynamic volume of S100A12 when calcium concentrations reach 
extracellular physiological levels (~1 mM) (85). 
 Gel filtration of S100A4 revealed multiple oligomeric states, which were 
correlated with potential to induce neurite outgrowth on cultured hippocampal cells. 
Fractions containing S100A4 tetramer or higher were necessary to induce neurite 
outgrowth (86). However, it is not clear whether the higher order oligomeric species are 
in equilibrium with the dimeric species. Thus, further studies involving mutations at key 
residues involved specifically in higher order oligomer formation are definitely required 
to test this proposal. 
 The x-ray crystal structure of S100A8/S100A9 heterodimer has three tetramers in 
the asymmetric unit (PDB 1XK4). Significant contacts are made between helices HIV of 
one dimer and the calcium binding loops of the second dimer. This tetramer interface 
places the traditional S100 target interacting surfaces of opposite dimers in proximity 
which could generate novel target recognition surfaces. Chemical crosslinking and mass 
spectrometry suggest calcium dependent tetramer formation of S100A8/S100A9 (87, 88). 
The crystal structure of S100A10 in complex with a peptide from annexin II also reveals 
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disulfide linked tetramers (75). In addition, a recently described crystal form of S100B 
shows the presence of four tetramers (89). It is intriguing to consider S100 
oligomerization in the context of receptor activation. Not only can a S100 dimer 
potentially dimerize a receptor (or alter the organization of a pre-formed receptor dimer), 
but higher order oligomers can multimerize or create novel binding surfaces for receptor 
recognition. 
 
Target Recognition by S100 Proteins 
 Multiple structures of S100 proteins bound to peptide fragments of cellular targets 
are available and reveal differences in the details of target recognition (64). Crystal 
structures of S100A10 and S100A11 bound to peptides from annexin II and annexin I, 
respectively, provided early insight into S100-target recognition (75, 90). In both cases, 
the annexin peptides adopt α-helical secondary structure and are bound to the S100 
protein in a calcium-dependent manner with a stoichiometry of two peptides per S100 
dimer (Figure 1.6). Thus, S100 proteins could function by oligomerizing target proteins, 
by bridging two different molecules, or by inducing conformational changes in proteins 
by binding to two different regions of one polypeptide. 
 The interaction between annexin peptides and their respective S100 proteins is 
stabilized by a combination of hydrophobic and hydrophilic interactions primarily in the 
shallow pocket formed between helices HIII and HIV. Unique to these two structures are 
contacts between the peptide and helix HI of the opposite subunit. This type of contact is 
absent in structures of S100B bound to target peptides from p53 and NDR kinase (Figure 
1.6) (91, 92). Nonetheless, the peptides adopt α-helical secondary structure and 
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contribute a combination of hydrophobic and hydrophilic side chains to stabilize the 
interaction. Earlier in this chapter I discussed multiligand recognition of structurally 
diverse molecules by RAGE. Ig domains do not contain a significant amount of α-helical 
secondary structure. Typically, 3-4 helical turns are required for efficient binding to S100 
proteins (Figure 1.6). Thus, the work described in this dissertation sets the stage to study 
the potentially novel interface used by S100 proteins to bind and activate RAGE. 
Figure 1.6: Variability in target recognition by S100 proteins. Displayed are the complexes of S100A10 with annexin II peptide (PDB 
1BT6), S100B bound to a p53 peptide (PDB 1DT7), and S100B bound to a NDR kinase peptide (PDB 1PSB). Ribbon diagrams 
shown with both subunits of the S100 dimer in black and the target peptides in red. Figure adapted from (64). 
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Mechanisms of Cytokine Receptor Signaling and Autoinhibition 
 RAGE functions as a signaling receptor. The structural work in this dissertation 
allows me to propose hypotheses about receptor activation taking advantage of the 
current knowledge available in the literature. A common theme within receptor activation 
is the concept of ligand induced oligomerization. An increasing level of sophistication in 
autoinhibition and activation models evolved as more information became available 
suggesting oligomerization is necessary but not sufficient for activity. In this section, I 
examine the available data on two well studied systems, growth hormone receptor (GHR) 
and erythropoietin receptor (EPOR), summarizing structural mechanisms of receptor 
autoinhibition and activation. 
 
Cytokine Receptor Classification 
 Cytokine receptors are integral membrane proteins sharing common features such 
as a large extracellular domain responsible for ligand binding, a single transmembrane 
helix, and an intracellular domain containing either intrinsic kinase activity or adaptor 
function to interact with kinases (93). The receptors are classified according to the size 
and complexity of their extracellular ligand binding domains. Traditionally, “simple” 
receptors contain only extracellular domains necessary for ligand binding and include 
GHR, EPOR, and the interleukin-4 receptor (IL-4R). “Complex” receptors contain 
structured domains not involved in ligand recognition but play a critical role in signal 
transduction, the best studied of which is the insulin receptor. 
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Scissor-like Activation of EPOR 
 Early studies in cytokine receptor function hypothesized the initial step towards 
activation required ligand-induced dimerization. For example, cysteine mutants in the 
extracellular region (containing two Ig-like domains D1 and D2) of EPOR (EPO binding 
protein, EBP) lead to disulfide linked dimers and constitutive activation (94). Production 
of a peptide that mimics receptor activation (EPO-mimetic peptide, EMP) and induces 
dimerization of EBP supported ligand-induced dimerization (95, 96). Additional EMPs 
that efficiently promote dimerization but lack the ability to activate the receptor have 
been characterized (97). Thus, the basic hypothesis was refined with the discovery that 
dimerization is necessary but not sufficient for activation. 
 The structure of unliganded dimeric EBP provides insight into the autoinhibition 
mechanism of EPOR shown schematically in Figure 1.7 (98). Analysis of this structure 
placed the membrane proximal D2 domains > 70 Å apart compared to the direct contacts 
between D2 domains observed in the x-ray crystal structure of erythropoietin bound to 
EBP (EPO-EBP) (99). Thus, the physical separation of the intracellular domains and 
bound kinases functions as the autoinhibited state. Ligand binding physically reorganizes 
the receptor bringing the bound kinases into proximity for trans-phosphorylation and 
signal activation. This scissor-like model is supported by a fluorescence complementation 
assay where two fragments of dihydrofolate reductase are fused to EPOR and transfected 
into Chinese hamster ovary cells. Intracellular binding of fluorescently conjugated 
methotrexate (which requires proximity of the two fragments) was only possible when 
the receptor was activated by ligand or when a 30 amino acid linker was present 
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providing extreme flexibility (the observations with this linker are also consistent 
preformed EPOR dimers) (100). 
 Comparisons of the x-ray crystal structures of EMP-EBP and EPO-EBP 
complexes revealed insights into subtle details of activation (96). The two EBP molecules 
show ~120° rotation in the crystal structure of the EPO-EBP complex (99). Two EMP-
EBP structures show relative rotations different from 120°. Since one EMP was inactive 
and the other was partially active, a logical conclusion is that a specific receptor 
orientation is required for efficient activation. Therefore, both proximity of the bound 
kinases and a specific orientation are required for signal transduction. 
 
Transmembrane Rotation Model for Activation of GHR 
 GHR was also thought to function through ligand-induced dimerization when a 
combination of titration calorimetry and gel filtration suggested a stoichiometry of 1:2 
between growth hormone (GH) and the ligand binding region of GHR (GHbp) (101). 
This stoichiometry was confirmed in the crystal structure of GH-GHbp (102). Studies 
using a variety of monoclonal antibodies that target the GHR extracellular domain show 
that dimerization is not sufficient for activation but that specific structural orientation of 
the receptor is necessary (103). Unlike EBP, GHbp exists as a monomer despite a 
combination of coimmunoprecipitation and FRET studies showing unliganded GHR 
dimers in cell culture (104). A mechanism for GHR signal activation has also been 
proposed and is depicted schematically in Figure 1.7. A series of alanine insertions were 
made between the transmembrane helix and the intracellular domain. Constitutive 
activation was achieved when exactly four alanines were introduced, which is predicted 
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to produce an ~40° net rotation (total of ~400°) of the intracellular domain if they 
continue α-helical secondary structure (104). Thus, unlike EPOR, which dimerizes 
through the extracellular domain in an inactive conformation physically separating the 
kinase adapter intracellular domain, GHR appears to dimerize through the 
transmembrane helix with its kinase adapter domains rotated in an orientation that 
autoinhibits trans-phosphorylation. 
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 Figure 1.7: Two models for cytokine receptor autoinhibition and activation. (A) Scissor-
like model for EPOR as described in the text. D1 and D2 domains of EPObp are shown in 
red and blue, respectively. JAK2 is shown as a blue circle associated with the 
intracellular domain. EPO is shown as a violet circle. Figure adapted from (99). (B) 
Rotation model for activation of GHR as described in the text. The two extracellular 
domains of GHbp are shown as red and blue 3D rectangles. One associated JAK2 is a 
blue circle and the other is a blue ellipse. GH binding (violet circle) induces rotation 
aligning the JAK2 molecules for activation. Figure adapted from (104). 
31 
Structural Studies on sRAGE and Ligand Interactions 
 The central focus of this dissertation is to understand the structure of RAGE and 
its function as a signaling receptor. Specifically, I describe the first detailed structural and 
biophysical characterization of sRAGE (Chapter II). The techniques used include limited 
proteolysis, a powerful approach for analyzing flexible regions of a protein (105). A 
combination of CD and NMR spectroscopy are used to determine the secondary and 
tertiary structure elements of sRAGE and single and tandem domain constructs. The 
combination of these experimental procedures revealed unique features of sRAGE 
quaternary structure. Further insights into sRAGE structure and function were obtained 
from a high resolution x-ray crystal structure of the tandem VC1 construct of sRAGE 
(Chapter III). Lastly, the interaction of sRAGE with two of its physiological ligands, 
S100B and CML, is characterized using a combination of protease protection, surface 
plasmon resonance, and NMR (Chapter IV). The combination of these results provided 
insight into sRAGE structure and RAGE-ligand interactions, the broader implications of 
which are discussed along with ideas about future directions for structure-based research 
on RAGE (Chapter V). 
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CHAPTER II 
 
THE EXTRACELLULAR REGION OF THE RECEPTOR FOR ADVANCED 
GLYCATION END PRODUCTS IS COMPOSED OF TWO INDEPENDENT 
STRUCTURAL UNITS 
 
 
Introduction 
 RAGE is a member of the immunoglobulin (Ig) superfamily containing three 
predicted Ig-like domains in its N-terminal ligand binding region (1). Further 
classification to an N-terminal V-type Ig domain and two subsequent C-type Ig domains 
was proposed based on sequence analysis; however, this assignment was based largely on 
homology to NCAM, whose β-strand topology has since been shown to differ slightly 
from V-type and C-type domains (106). 
 As described in Chapter I, a critical aspect to understanding mechanisms of 
receptor signaling is obtaining information on the natural or ligand-induced quaternary 
structure of the receptor. In fact, while the general tertiary structure of the domains in 
sRAGE is assumed to be a two-sheet β-sandwich stabilized by an internal disulfide bond, 
little information is known about sRAGE quaternary structure. In this chapter, production 
protocols for sRAGE and a series of domain constructs are developed to establish a 
foundation for structural studies. Subsequently, the issue of sRAGE quaternary structure 
is addressed using limited proteolysis, which can identify variability in structured vs. 
unstructured regions of the protein (105). Lastly, the relationship of the three Ig domains 
is assayed by characterizing their thermal denaturation midpoints and analyzing 
multidimensional NMR spectra and a homology model for the tandem VC1 domains. 
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Production of sRAGE and Domain Constructs 
 High level production and purification protocols were developed for sRAGE and 
the five single and tandem domain constructs (VC1, C1C2, V, C1, C2; see Figure 1.1). 
While the production of recombinant sRAGE has been described for both eukaryotic and 
prokaryotic expression systems (43, 107-109), the strategy described here provided 
consistent high level production of all six constructs without the need to refold protein 
from inclusion bodies. Bacterial expression vectors were constructed that enable 
purification via an N-terminal His6-tag and nickel affinity chromatography (see Chapter 
VI). Use of cells providing an oxidizing environment and optimization of expression 
parameters (temperature, duration, IPTG concentration) produced soluble protein for 
each of the constructs. Protein yields after purification were similar for sRAGE, VC1, V, 
and C2 (15-20 mg/L) and lower for C1C2 and C1 (5-10 mg/L) as a result of their lower 
expression levels. 
 When performing structural analysis on isolated domains of a protein, it is 
important to properly define construct boundaries. Initial boundaries were based on 
sequence alignment with known Ig family sequences and secondary structure prediction. 
Ala23 represents the first amino acid of the native receptor after loss of the signaling 
peptide and was selected as the N-terminus for our sRAGE construct. The C-terminus of 
sRAGE, Gly327, represents the end of the C2 structural region, which is linked to the 
transmembrane helix. The N-terminus for the V and VC1 constructs and the C-terminus 
for the C1C2 and C2 constructs were the same as for sRAGE. The predicted linker region 
separating C1 and C2 was identified by multiple sequence alignments of four RAGE 
genes (human, bovine, rat, and mouse; Figure 2.1). The eleven amino acid insert in 
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bovine RAGE after Trp230 aided identification since regions of low identity and 
homology often represent loop and linker regions. The intervening boundaries between V 
and C1 proved to be more challenging to precisely identify and had to be manually 
optimized based on expression level, solubility, and stability. This analysis suggests there 
may be unique features relating V to C1. 
 
 
Figure 2.1: Multiple sequence alignment of RAGE proteins. From top to bottom, human 
(Q15109), bovine (Q28173), rat (Q63495) and mouse (Q62151) RAGE were aligned 
using ClustalX run on a Windows PC. The numbering on the top represents the residue 
number of the human sequence. The symbol (*) denotes 100% conservation while the 
symbols (:) and (.) represent high and moderate conservation, respectively. See Appendix 
A for full sequence alignment. 
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 Analysis of purified constructs under reducing and non-reducing SDS-PAGE 
conditions showed a mobility shift consistent with formation of disulfide bonds. 
Observing a single band under non-reducing conditions suggested homogeneity in 
disulfide formation. Interestingly, 15N-1H HSQC spectra of V acquired in the presence of 
reducing agent showed a collapse of the chemical shift dispersion in the 1H dimension, 
which is characteristic of an unfolded protein (Figure 2.2). This suggests any experiments 
in the presence of reducing agents could lead to artifacts due to protein unfolding. 
 
 
Figure 2.2: The effect of reducing agent on Ig domain tertiary structure. (A) 15N-1H 
HSQC spectrum of isolated V in the absence of DTT acquired according to Chapter VI. 
(B) 15N-1H HSQC spectrum of V in the presence of 1 mM DTT. 
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Stability of sRAGE Domains 
 A series of limited proteolysis experiments were performed in order to further 
characterize the domain structure of sRAGE. A time course for digestion of the protein 
by trypsin shows that sRAGE is completely digested within four hours (Figure 2.3A). 
Two major species are formed during early time points, one migrating at ~25 kDa (Figure 
2.3A, arrow b) and another at ~12 kDa (Figure 2.3A, arrow c). In-gel digestion of the 25 
kDa band with trypsin followed by MALDI-MS analysis showed this band contained 
peptides unique to the V and C1 domains. Figure 2.3B shows the sequence coverage 
obtained for both intact sRAGE (Figure 2.3A, arrow a) and the ~25 kDa fragment. 
Notably, coverage obtained for the V and C1 domains was nearly complete in the 25 kDa 
band (Figure 2.3A, arrow b), ranging from a peptide encoding a region of the N-terminus 
(23-29) to a peptide near the C-terminus of C1 (199-216). 
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 Figure 2.3: Limited proteolysis of sRAGE reveals two stable domains. (A) Reducing 
SDS-PAGE of sRAGE digested by trypsin (500:1, w/w) at room temperature. Arrows at 
right highlight the three main fragments. Each of these bands shift in mobility when gels 
are run under non-reducing conditions indicating they contain one or more disulfide 
bonds. Time points are given in minutes. (B) Sequence of recombinant sRAGE after 
removal of His6-tag. The first four amino acids (GSHM) remain after thrombin cleavage. 
Ala23 is the first amino acid of the mature protein after the signal sequence is removed. 
Highlighted in bold are peptides observed in mass spectrometry analysis of the 
trypsinized 25 kDa band (band “b”) in panel (B). The only peptide observed in the mass 
spectrometry analysis of band “a” that is not seen in band “b” is underlined. The 
numbering on the right corresponds to the last amino acid in each row. 
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 To further confirm the origin of the 25 kDa band, limited proteolysis of VC1 
(Figure 2.4) was performed under conditions identical to those used for sRAGE. 
Digestion of VC1 produced a small truncation to a band with the same mobility as the 25 
kDa band generated from sRAGE digestion (arrow d, Figure 2.4). Both the intact VC1 
and the 25 kDa fragment were digested at the same rates as those observed in the 
experiment with sRAGE. Notably, the 25 kDa fragment produced from either sRAGE or 
VC1 digestion was largely stable to further proteolysis despite the presence of both lysine 
and arginine residues in the expected linker region between the two domains. To further 
understand the apparent stability of the V-C1 linker we performed limited proteolysis 
experiments on isolated V and C1. Figure 2.4 shows that both intact V and especially C1 
were much more susceptible to trypsin proteolysis than the 25 kDa fragment that 
contained both V and C1. Furthermore, we failed to observe a truncation to a stable 
fragment for either construct that would indicate the presence of a single stable V or C1 
domain. 
 
 
Figure 2.4: Resistance to proteolysis of V and C1 is enhanced by covalent attachment. 
Reducing SDS-PAGE analysis of VC1, V, and C1 proteolyses by trypsin (500:1, w/w). 
The mobility of band “d” and that for the intact protein shift when run under non-
reducing conditions. Time points are given in minutes. 
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 Unlike sRAGE and VC1, the C1C2 construct was completely digested by trypsin 
in 5 minutes, and only a single 12 kDa band was observed thereafter (Figure 2.5, arrow 
e). This stable band had identical mobility to the 12 kDa band seen in the sRAGE 
digestion (Figure 2.3, arrow c). The presence of this band in sRAGE and C1C2 
digestions, but not for VC1, implies the band belongs to the C2 domain. Exposure of 
isolated C2 to trypsin showed it is completely stable to digestion by this protease (Figure 
2.5). This observation is identical to that made for the 12 kDa band in the sRAGE (Figure 
2.3, arrow c) and C1C2 digestions. The assignment of the 12 kDa band to C2 and the 
absence of other bands in C1C2 digestions indicate that the C1 domain on its own is not 
stable. 
 
 
Figure 2.5: The C2 domain is stable to trypsin proteolysis. Reducing SDS-PAGE 
analysis of C1C2 and C2 by trypsin (500:1, w/w) at room temperature. The mobility of 
band “e” corresponds to the ~12 kDa band “c” in Figure 2.3A. Time points are given in 
minutes. 
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 Differential scanning calorimetry (DSC) experiments were performed to better 
understand the stability and interdependence of sRAGE domains. Intact sRAGE showed 
a single thermal transition with a Tm at 55.1 °C, which was surprising given the much 
higher Tm value of isolated C2 (vide infra). Unfortunately, heating beyond 60 °C leads to 
aggregation and precipitation (Figure 2.6, solid line), which precludes further analysis. 
VC1 responded in a very similar manner, with a single transition corresponding to Tm at 
55.1 °C followed by aggregation and precipitation (Figure 2.6, dashed line). 
 
 
Figure 2.6: VC1 undergoes a complex thermal transition. DSC thermograms are shown 
for sRAGE (−), VC1 (--) and C2 (··). Experimental details are described in Chapter VI. 
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 In an attempt to determine if the thermal transition derives specifically from one 
domain, DSC experiments were performed on isolated V and C1. However, although the 
proteins remained soluble, no discrete transitions were observed for either of the isolated 
domains (Figure 2.8A). These observations are consistent with the limited proteolysis 
experiments, which suggested that isolated V and C1 are not stably folded independent 
domains. Based on the evidence from the thermal denaturation and limited proteolysis 
data, we attribute the unfolding event at 55 °C to uncoupling of the V and C1 domains. 
Remarkable parallels are found in a very thorough study of the unfolding of a tandem 
(one V-type and one C-type domain) Ig protein from a multiple myeloma κI light chain, 
from which the authors concluded that the phenomena observed did not correspond to 
unfolding of independent structural domains (110). As an alternative to the DSC 
approach, the temperature dependence of the CD spectrum of VC1 was examined. The 
rationale is that the degree of unfolding of the protein would be reflected in the degree of 
loss of CD ellipticity. Since the protein precipitates at higher temperatures, the maximum 
temperature was restricted to 55 °C. Figure 2.7 shows a reversible (and incomplete) loss 
of CD ellipticity is observed as the temperature is raised. The reversibility of the thermal 
melt rules out precipitation as the only contributing factor to the CD transition. In 
addition, the retention of significant secondary structure (~60%) is consistent with 
uncoupling of V and C1, and not global unfolding, as interpreted for the DSC results. 
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 Figure 2.7: CD thermal melt of VC1. Shown are the melting (−) and subsequent cooling 
(··) of VC1 from 25 °C to 55 °C. Raw data were converted to mean residue ellipticity 
according to Chapter VI. The difference in mean residue ellipticity at 25 °C is consistent 
with a small amount of protein precipitation during the experiment. 
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 Analysis of C1C2 and C2 constructs showed a single unfolding transition with Tm 
values of 72.7 °C and 74.3 °C (Figure 2.8B; Figure 2.6, dotted line), respectively. In both 
cases this transition was nearly 100% reversible. This distinct thermal transition is 
attributable to unfolding of the C2 domain, which supports our limited proteolysis data 
suggesting that C2 is independent from the rest of the sRAGE molecule. Note that the 
unfolding transition for C2 in the context of full sRAGE was not observed because it was 
masked by the aggregation/precipitation associated with VC1 that occurs well below the 
Tm of C2. Taken together, the limited proteolysis and DSC data imply that the three 
predicted domains are present. However, whereas C2 is a completely independent and 
highly stable domain, V and C1 are seen to have a significant influence on each other’s 
stability. 
 
 
Figure 2.8: Thermal stability of V, C1, and C1C2 constructs. (A) DSC thermograms for 
V (−) and C1 (··). Shown is one of many inconsistent results. (B) DSC thermogram for 
C1C2. Experimental details are described in Chapter VI. 
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sRAGE is Composed of Coupled V and C1 Domains With an Independent 
C2 
 
 Circular dichroism, dynamic light scattering, and NMR were used to characterize 
the secondary and tertiary structure and the oligomeric state of sRAGE and domain 
constructs. CD provided distributions of secondary structure elements for each of the six 
protein constructs, all of which showed a combination of β-sheet and random coil (Figure 
2.9). Remarkably, sRAGE, VC1, C1C2, and C2 all were assigned 47% β-sheet, 48% 
random coil, and 5% α-helix, and only slightly reduced β-sheet and increased random 
coil was observed for isolated V (40% β-sheet, 51% coil) and C1 (43% β-sheet, 48% 
coil). These results show all six protein constructs contain secondary structure highly 
consistent with one or more Ig-like folds. 
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 Figure 2.9: Circular dichroic spectra of sRAGE and domain constructs. CD spectra are 
shown for sRAGE (black), VC1 (pink), C1C2 (dark red), V (yellow), C1 (turquoise), and 
C2 (violet). Data shown are representative of at least three accumulations. All data were 
collected, converted to mean residue ellipticity, and secondary structure content estimated 
as described in Chapter VI. 
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 The tertiary structure of sRAGE and each of the tandem and single domain 
constructs was analyzed by 15N-1H HSQC NMR (Figure 2.10). Despite the relatively 
small size of the three domains, it was surprisingly difficult to obtain high quality NMR 
spectra. Experimental conditions (temperature, pH, and ionic strength) for each construct 
had to be optimized independently. Dynamic light scattering was also used to 
complement the NMR experiments, in particular to assess whether the domain constructs 
were monomeric under the conditions of the NMR experiments. Hence, the light 
scattering data were collected at the same protein concentrations as those used in NMR 
experiments. 
 In the 15N-1H HSQC spectrum of sRAGE, less than 100 crosspeaks were observed 
(Figure 2.10A). The linewidths of these signals were relatively narrow, as would be 
expected for a single Ig domain. Moreover, the signals correspond precisely to the peaks 
observed in the corresponding spectrum of isolated C2 (Figure 2.10F). Since the NMR 
chemical shift is an exquisitely sensitive probe of structure, these observations indicate 
that the observed peaks in the sRAGE spectrum arise from C2. Of note, signals in both 
spectra have uniform intensity and line width and are well dispersed, consistent with a 
well-folded globular domain. In addition, light scattering data on isolated C2 were fit to a 
mean radius of 2.21 ± 0.27 nm with a polydispersity of 12%, fully consistent with a 
monomeric non-spherical β-sandwich. 
 An interesting question is why the V and C1 peaks from sRAGE are so much 
broader than the C2 peaks that they are not observed in a standard HSQC spectrum. Since 
previously published analytical ultracentrifugation experiments showed that sRAGE is 
monomeric (107), the likely explanations are the two domains tumble in solution with the 
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characteristics of a larger particle or that they are both conformationally heterogeneous. 
To obtain further insight, light scattering experiments were performed on sRAGE to 
verify that the protein is monodisperse. Unfortunately, the data were ambiguous because 
the level of polydispersity assigned (33.5%) is above the threshold for which reliable 
conclusions can be drawn. [I believe sRAGE is not poly-disperse, but rather that the 
fitting of light scattering data is not straightforward because sRAGE contains two 
independent, flexibly linked structural modules.] The smaller VC1, V and C1 constructs 
were then used to obtain further insights. 
 The 15N-1H HSQC spectrum of VC1 showed at least 150 distinct backbone peaks 
out of a maximum of ~200 (Figure 2.10B), as expected for a protein of this size. Not 
every peak will be discernable in a 2D experiment because those in the crowded central 
region are likely to overlap. Importantly, the relatively sharp and well dispersed peaks 
from C2 observed in the spectrum of sRAGE were clearly not present in the spectrum of 
VC1. Moreover, the linewidths of the peaks in the VC1 spectrum were significantly 
larger than those observed for the C2 domain in the spectrum of sRAGE. Light scattering 
data on VC1 were fit to an average radius of 3.43 ± 0.33 nm with a low level of 
polydispersity (9.5%). The radius suggests an elongated molecule consistent with the 
homology model generated for VC1 described below in addition to the ellipsoid structure 
modeled from analytical ultracentrifugation (107), and indicates that the VC1 protein is 
monomeric. The ability to observe a rather complete and well-dispersed 15N-1H HSQC 
spectrum for VC1 with relatively uniform peak intensities, combined with the light 
scattering analysis and the lack of signals for VC1 residues in the spectrum of sRAGE, 
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strongly implies that the V and C1 domains are well-folded and suggests that they tumble 
as an integrated structural unit. 
 
Figure 2.10: Heteronuclear NMR spectra of RAGE constructs. 15N-1H HSQC spectra are shown for sRAGE (A), VC1 (B), C1C2 (C), 
V (D), C1 (E), and C2 (F). The data were collected at 600 (C1C2, C1) or 800 (sRAGE, VC1, V, C2) MHz at 25 °C. Solution 
conditions are provided in Chapter VI. 
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 To further verify the conclusions from the analysis of VC1, the use of specialized 
techniques to improve the sRAGE spectrum including TROSY and perdeuteration of the 
protein was investigated (111, 112). Perdeuteration in particular provided a substantial 
improvement (Figure 2.11), and resulted in well over 200 discrete peaks in the spectrum. 
Interestingly, there are two populations of peaks in the spectrum of perdeuterated sRAGE 
with different relative intensities and linewidths. Many peaks from the subset with lower 
intensity/wider linewidths were well dispersed into both upfield and downfield regions 
and corresponded well with peaks in the spectrum of VC1 (Figure 2.11, red circles). The 
subset with higher intensity/narrower linewidths overlap well with the C2 peaks observed 
in the spectra of protonated sRAGE, C1C2, and C2 (Figure 2.10A, 2.10C, 2.10F, Figure 
2.11, green circles). Together, these observations show that V and C1 are indeed folded 
in the context of sRAGE and that the lower intensity/wider linewidth peaks in the 
spectrum of sRAGE arise from these domains. The fact that linewidths of peaks from the 
V and C1 domains are the same and significantly larger than those of C2 strongly implies 
that V and C1 form an integrated structural unit. 
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 Figure 2.11: VC1 and C2 are separate structural units. 15N-1H HSQC spectrum of 
perdeuterated sRAGE is shown with peaks labeled based on direct comparison to the 
spectra of VC1 and C2. Red circles denote crosspeaks uniquely assigned to VC1 and 
green circles denote crosspeaks uniquely assigned to C2. Unmarked crosspeaks represent 
those that are overlapped or are not sufficiently unique to be confidently assigned by 
comparison to one of the two sub-spectra. 
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 Further support for the structural integration of the V and C1 domains was 
obtained from comparisons to the chemical shifts of isolated V and C1 (Figure 2.10). The 
15N-1H HSQC spectrum of C1 is highly heterogeneous, with a large excess of peaks. In 
addition to a number of well dispersed peaks, a large number of overlapped peaks in the 
central region are observed along with a significant variation in signal intensity (Figure 
2.10E). Light scattering experiments revealed a very high 39.2% level of polydispersity. 
These observations are indicative of a heterogeneous C1 domain with substantial 
unfolded or partially folded regions. The 15N-1H HSQC spectrum of isolated V (Figure 
2.10D) has about the expected number of peaks but linewidths are significantly larger 
than the peaks observed in the spectrum of the well-folded C2 domain. The larger 
linewidths of V are presumably the result of conformational heterogeneity as observed 
for C1 or possibly compounded by some self-association, both as a byproduct of 
separation from C1. The high level of polydispersity (34.5%) in light scattering on this 
domain is consistent with a lack of structural stability and a tendency to aggregate. 
 Despite the complications of working with the isolated V and C1 domains, 
detailed comparison of NMR chemical shifts of V, C1, and VC1 could be performed to 
obtain domain-specific assignments. This was possible because many peaks in the 
spectrum of VC1 could be assigned to the V or C1 domain since they appeared in a 
nearly identical and distinctive location in the spectrum of both VC1 and the 
corresponding isolated domain. In addition to these peaks that correspond very closely, 
there were a number of characteristic peaks in the spectra of isolated V and C1 that 
appear in clearly different locations in the spectrum of VC1, as shown in Figure 2.12. For 
the V domain, approximately 50 peaks outside the crowded 8.0-8.5 ppm 1H region could 
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be distinguished. Among these, approximately 20 were clearly shifted relative to their 
position in the spectra of VC1 and sRAGE. A number of readily distinguishable C1 peaks 
could also be identified, but the analysis was not nearly as complete due to the 
heterogeneity of C1. Regardless, there is sufficient data to conclude that there are 
perturbations of peaks in the downfield dispersed region, which indicates that the 
structure of V is altered by the presence of C1 and vice versa, i.e. there is a specific 
structural interface between V and C1. In summary, these data show the V and C1 
domains of sRAGE form an integrated structural unit that is structurally independent of 
and dynamically linked to the C2 domain. 
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 Figure 2.12: The V and C1 domains form a discrete structural interface. Comparison of 
the heteronuclear NMR spectra of isolated V construct and the tandem VC1 construct. 
The 15N-1H HSQC spectrum of isolated V is shown. Red circles mark the position of 
same crosspeaks in the spectrum of VC1. Lines are drawn between a crosspeak in the V 
spectrum and the crosspeak of nearest proximity in the VC1 spectrum. Unmarked 
crosspeaks either do not experience significant chemical shift perturbations or cannot be 
analyzed due to overlap. 
  
55 
Homology Modeling of sRAGE 
 A homology model of the three-domain sRAGE protein was constructed using 
MODELLER software via the ESyPred3D web server in order to facilitate analysis of the 
structural data and better understand the implications for cellular signaling. An extensive 
database of Ig-like domain sequences and structures are available, which implied a high 
quality model could be generated. The automated pairwise alignment module selected 
NCAM (PDB 1QZ1) as the template protein because it has 19% identity with sRAGE 
after alignment. However, the structure of NCAM has no significant linkers between any 
of the domains, which differs from our analysis of sRAGE. Thus, models of VC1 and C2 
were generated separately. 
 The pairwise alignments against VC1 resulted in highest homology with an Fab 
light chain (PDB 1IQD), which has 17.6% identity, so this structure was used to generate 
the model (Figure 2.13A). Figure 2.13B shows the final pairwise alignment of VC1 with 
the template, which reveals that many of the residues involved in interdomain packing are 
not conserved. Hence, the intimate details of the interdomain packing and orientation in 
the model are viewed as an approximation. On the other hand, the global features of the 
model have a very high likelihood of being accurate. The high quality of the VC1 model 
is reflected in an analysis with PROCHECK, e.g. 87% of residues are in most favorable 
conformations, 11% in the additionally allowed region, and 2% in the generously allowed 
region. Similar high quality results were obtained for the C2 domain, which was modeled 
from human APEP-1 and is presented in Chapter V (PDB 1U2H, Figure 5.1). 
 The VC1 homology model predicts globular structure for residues Asn25-Thr222. 
Thus, in the VC1 construct (Ala23-Glu243) used in our experimental studies, most of the 
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C-terminal 21 residues are predicted to be unstructured because they span the C1-C2 
linker and into the C2 domain. In the model, the linker between V and C1 is predicted to 
be only three residues in length, Gln119-Pro121, since Tyr118 forms backbone hydrogen 
bonds to a β-strand in the V domain and Gly122 forms backbone hydrogen bonds to a β-
strand in the C1 domain (Figure 2.13A). A critical aspect of the model is that these three 
linker residues are predicted to contribute to interdomain packing along with several 
residues from the V domain (Thr27, Glu94, Arg114, Arg116, Val117, Tyr118) and the 
C1 domain (Tyr150, Ala152, Arg178, Arg179, Thr183, Gly184, Phe186). The solvent 
accessible surface of V and C1 that is buried in the VC1 model is ~500 Å2 in each 
subunit. Although the relatively small size of this interface suggests that the intrinsic 
affinity of the two domains is relatively weak, the interaction between the domains will 
be enforced by the short length and structural integration of the linker. This interpretation 
is supported by the lack of chemical shift perturbations in NMR experiments acquired for 
mixtures of isolated V and C1 domains. Thus, the model is fully consistent with the 
observation that V and C1 have a structural interface and tumble as an integrated 
structural unit. 
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 Figure 2.13: Homology modeling of VC1. (A) Ribbon diagram of the homology model 
of VC1 with the V domain (25-118) shown in red, the linker (119-121) in black, and the 
C1 domain (122-222) in blue. Side chains for the linker residues are shown as black 
wires. Side chains for V and C1 involved in interdomain packing are shown in space 
filling representation in the respective colors for the domains. The side chain of Trp51 is 
shown as black wire. The side chains for the two cysteine residues in the V domain are 
shown in ball and stick colored according to atom (grey, carbon; yellow, sulfur). (B) 
Pairwise alignment of VC1 with the A chain of PDB molecule 1IQD. Residues in the 
linker region are in bold. Residues involved in interdomain packing are highlighted in the 
respective colors used in (A) (V, red; C1, blue; linker, black). 
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Summary 
 As described in Chapter I, RAGE is involved in numerous aspects of biology and 
pathology ranging from neural growth and development to tumor growth and metastasis. 
After establishing an E. coli expression system that takes advantage of OrigamiB cells 
that have a cytoplasm with an oxidizing environment and allows disulfide bond formation 
during protein expression, milligram quantities of sRAGE and domain fragments could 
be produced for subsequent biochemical, biophysical, and structural characterization. 
 A series of biochemical analyses including limited proteolysis and 
characterization of thermal denaturation were used to characterize sRAGE. Limited 
proteolysis initially suggested that the highest degree of flexibility was between C1 and 
C2. Additionally, powerful observations were made that V and C1 were much more 
stable to digestion when covalently attached. Differential scanning calorimetry further 
suggested structural independence since VC1 and C2 appear to experience separate 
unfolding transitions. These observations led to the use of structural biology to further 
characterize sRAGE. 
 First, qualitative analysis of NMR spectra was used characterize the quaternary 
structure of sRAGE. These studies revealed that the C1-C2 linker has a high degree of 
flexibility. The structural independence of the VC1 region from the C2 domain was 
clearly evident from the similarity of C2 chemical shifts observed for all sRAGE 
constructs containing C2. In contrast, the V and C1 domains have a discrete structural 
interface as reflected by chemical shift differences between VC1 and the isolated V and 
C1 domains. Second, a computational homology model of VC1 provided insight into the 
details of the interdomain interface explaining the observation that they behave as an 
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integrated structural unit. The implications of these results are discussed with respect to 
mechanisms of cell signaling in Chapter V. Finally, this work provided novel insight into 
sRAGE quaternary structure and defined the proper constructs needed for high resolution 
structure determination of VC1, which is analyzed in the next chapter. 
60 
CHAPTER III 
 
HIGH RESOLUTION CRYSTAL STRUCTURE OF VC1 
 
Introduction 
 RAGE is a member of the immunoglobulin (Ig) superfamily containing three 
predicted Ig-like domains in its large extracellular ligand binding region (1). In Chapter 
II, I described the first biochemical and structural characterization of RAGE which 
revealed that the V and C1 domains tumble as an integrated structural unit with the C2 
domain flexibly attached. A homology model of VC1 revealed a significant structural 
interface between V and C1. However, due to lack of sequence homology to the template 
structure at the interface I could not conclude that either the interdomain angle or the 
specific side chain packing between V and C1 was accurate. 
 From the results reported in Chapter II, the linker between C1 and C2 was 
estimated to be at least 10 residues. High sequence homology (except for the bovine 
protein which has a large insert that could increase flexibility) suggests the structural 
flexibility of the C1-C2 linker is highly conserved across species (Figure 2.1). Since the 
accuracy of a model is dependent on homology to the template, important details can be 
different once the structure is determined. For example, the V-C1 interdomain angle and 
the precise length of the C1-C2 linker could be critical in autoinhibition and activation of 
RAGE. In order to better understand the basis for RAGE signaling, Dr. Guenter Fritz 
used constructs designed from the biochemical analysis to determine the x-ray crystal 
structure of the tandem VC1 construct to 1.8 Å (statistics in Appendix B). This high 
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resolution structure allowed a detailed analysis of the V-C1 interface and sets the stage 
for understanding ligand-induced signal transduction and the structural determinants of 
interdomain flexibility, both of which are presented in this chapter. 
 
Crystallization and Structure Determination 
 The VC1 construct and purification protocol were generated as described in 
Chapter VI. Initial protein samples were prepared at Vanderbilt University, but 
eventually the expression vector was sent to Germany along with a detailed protocol. 
Purified VC1 was prepared at a concentration of 10 mg/ml and buffer exchanged into 10 
mM sodium acetate at pH 4.5. Crystals were grown at 298 K by mixing 2 µl of the 
protein solution with 2 µl of 0.1 M sodium cacodylate at pH 6.5, 0.2 M zinc (II) acetate, 
11% PEG 8000. Crystals grew to a size of 200 µm x 100 µm x 200 µm after 10-20 days. 
 For cryoprotection, the crystals were soaked for 1 min in three consecutive steps 
in mother liquor progressively containing 4, 8 and 12% glycerol and flash frozen in liquid 
nitrogen. Native crystals diffracted to a resolution of 1.8 Å. As zinc (II) turned out to be 
essential for crystallization it was assumed that zinc (II) specifically interacts with VC1 
and therefore could be used for experimental phasing. Multiple anomalous dispersion 
data were collected at the Swiss Light Source (Villigen, CH) beamline X06SA. The data 
sets were reduced and scaled with the XDS package (113). Crystals belonged to the space 
group P21212 with unit cell parameters of 74.63 119.68 28.82 as determined by XPREP 
(Bruker-AXS, 2005). The zinc substructure was solved using SHELXD (114). 
Refinement of the zinc sites and phase calculation was done with SHARP (115) followed 
by solvent flattening and initial fragment building using RESOLVE (116). The final 
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model was built manually in COOT (117) followed by several cycles of restraint and TLS 
refinement as implemented in REFMAC5 (118, 119). All stages of crystallization and 
structure determination were performed by Dr. Guenter Fritz at the University of 
Konstanz in Germany. I performed the analysis of the structure described in the following 
sections. 
 
 
Figure 3.1: The x-ray crystal structure of VC1. Ribbon diagram of VC1 colored 
according to figures in Chapter II. The V domain (23-118) is in red and the C1 domain 
(119-233) is in blue. A portion of the C-terminal extension (231-233) is shown in black. 
Panel (B) is a 90 degree rotation of panel (A) towards the top of the page. The individual 
strands are labeled for the V domain (A) and C1 domain (B) according to topology 
shown in Figure 3.2. The c' strand of the C1 domain is labeled in panel (A). 
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Structural Characteristics of VC1 
 The structure of VC1 is composed of two integrated Ig-like domains (Figure 3.1). 
The 2D topology diagrams for each domain are shown in Figure 3.2. The N-terminal 
domain has characteristic V-type topology exemplified by sheet swapping of the first β-
strand (strand a) forming a parallel β-sheet with the last β-strand (strand g; Figure 3.1A). 
Strands a, c, c', f, and g form one sheet while strands b, d, and e form the second sheet. 
Another characteristic of V-type Ig domains is additional residues between strands c and 
d labeled c' and c''. The c' strand clearly extends the anti-parallel β-sheet while c'' 
functions merely as a long loop leading into strand d. The lack of the c'' strand sometimes 
classifies the Ig domain as a C/V hybrid; however, strand a swapping is unique amongst 
V-type Ig domains and confirms this assignment (120). 
 The C-terminal domain forms an apparent H-type fold with strands a, b, c', d, and 
e forming one sheet and strands c, f, and g forming the second sheet of the β-sandwich 
(120). Strand c' is very short only containing residues 162-163. As anticipated, disulfide 
bonds are present between residues Cys38 and Cys99 of the V domain and Cys144 and 
Cys208 of the C1 domain. While C1 should be classified as an H-type Ig domain, the 
nomenclature ‘C1’ will continue to be used for consistency with previous chapters. 
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 Figure 3.2: Topology diagram of the x-ray crystal structure of VC1. (A) Topology 
diagram of the V domain in VC1. Each strand is denoted as an arrow with the strand label 
on the right where strand a and strand g are the N- and C-termini respectively. (B) 
Topology diagram of the C1 domain in VC1. Strands depicted and labeled as in (A). 
 
 Overall the topology and hydrogen bonding pattern of both domains is quite 
standard, although two deviations stood out. Strand g of the C1 domain contains residues 
Leu220 through Gln226, however, there is a bulge at Ala223 and Pro224 (Figure 3.1B, 
directly below the strand g label). The typical backbone hydrogen bond between the 
carbonyl oxygen of Ala223 and the amide proton of Cys208 on the adjacent β-strand is 
absent and is replaced by hydrogen bonds between the Thr222 hydroxyl side chain and 
backbone atoms from Ala223 and Cys208 (Figure 3.3). The residues of strands f and g in 
C1, which includes the bulge, are 100% conserved across species except for Arg221 
(Appendix A). 
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 Figure 3.3: Side chain hydroxyl stabilizes a bulge in a C1 β-strand. Backbone and side 
chain heavy atoms are shown for the region of the C1 domain containing a bulge in 
hydrogen bonding pattern. Thr222, Ala223, and Cys208 are colored according to atom 
type (C, grey; N, blue; O, red) with the rest of the atoms and bonds in black. Potential 
hydrogen bonds are shown as thin cyan lines. The side chain of Thr222 is in proximity to 
form hydrogen bonds most likely with backbone oxygen and nitrogen atoms of Ala223 
and Cys208 respectively. 
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 A second interesting feature is present at the C-terminus of C1. Residues 228 
through 231 of strand g swap and form a short parallel β-sheet with strand a near the C1A-
B loop. This causes a break in β-sheet hydrogen bonding and an exaggerated rolling of the 
sheet at the N-terminus of strand b (Figure 3.4). In conjunction with this break, the β-
sheet hydrogen bonding between strands f and g is broken at Pro227. The proline is 
replaced by leucine in both the bovine and mouse sequences, in which the amide nitrogen 
of Leu227 would be in register to hydrogen bond to the carbonyl oxygen of Pro204 on 
strand f. One anticipates a different conformation in these proteins. Other forces such as 
side chain packing could drive the formation of this short parallel β-sheet even in the 
bovine and mouse proteins; computational analysis or structure determination would be 
required to resolve this question. 
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 Figure 3.4: Strand swap at the C-terminus of the C1 domain. Expanded view of the C-
terminal region of the C1 domain in the orientation shown in Figure 3.1B. Ribbon 
diagram is colored according to average % conservation from unconserved (dark blue, 
none shown) to fully conserved (red, majority of structure). Potential hydrogen bonds are 
shown as thin cyan lines. The side chain for Pro227 (conserved in 2 of 4 species, 
Appendix A) is depicted in stick representation. 
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 Comparing the individual domains provided significant insight into the accuracy 
of the homology model presented in Chapter II. The orientation and topology of β-strands 
of the V domains in the homology model and x-ray crystal structure are similar (Figure 
3.5A). However, the two structures have a RMSD from the mean structure of 2.2 Å when 
aligned according to the β-strands. The most dramatic differences are in the loops 
opposite to the V-C1 interface. For example, the VB-C loop in the crystal structure is 
flipped out of the plane of the β-sandwich. Consequently, the VF-G loop in the homology 
model is flipped into the β-sandwich plane to maintain side chain packing between the 
loops. 
 The orientation and topology of β-strands of the C1 domains from the homology 
model and x-ray crystal structure also appear to be similar (Figure 3.5B). However, the 
two structures have a RMSD from the mean structure of 2.9 Å when aligned according to 
the β-strands, slightly higher than the alignment of the V domains. Like the V domains, 
the most dramatic differences are in loop regions at the ends of the β-sandwich opposite 
to the interdomain interface (Figure 3.5B, circled). Specifically, significant differences 
are observed in the C1A-B  loop (Figure 3.5B). The loop no longer extends beyond the β-
sandwich due to introduction of approximately 1.5 turns of α-helix. The C1E-F loop 
likewise adopts a different orientation since side chains pack between the C1A-B and C1E-F 
loops. 
 In summary, the x-ray crystal structure of VC1 is consistent with the initial 
sequence analysis and homology modeling. An N-terminal V-type Ig domain and a C-
terminal H-type Ig domain are found. The details of the experimental structure suggest a 
short sequence of β-strand (c') between strands c and e which is more consistent with an 
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H-type Ig fold as opposed to the originally assigned C-type Ig fold. A more detailed 
analysis of the x-ray crystal structure will be made in the next section to determine if the 
hypotheses generated in Chapter II about sRAGE quaternary structure are supported. 
Figure 3.5: Comparison of the homology model and x-ray crystal structure of VC1. (A) Overlay of the V domain from the homology 
model (green) and the x-ray crystal structure (red). The orientation is the same as in Figure 3.1A. (B) Overlay of the C1 domain from 
the homology model (green) and the x-ray crystal structure (blue). The orientation is the same as in Figure 3.1A. Overlays were made 
by superimposing backbone atoms and minimizing the RMSD using Chimera (39). 
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The V-C1 interface 
 In Chapter II, a series of biochemical and modeling data were used to generate 
hypotheses about sRAGE quaternary structure. The critical observation was that V and 
C1 tumble as an integrated structural unit while C2 has significant structural flexibility 
from VC1. Aligning the VC1 tandem domain structures through the C1 domain shows 
there is a striking difference in the V-C1 interdomain angle between the model and the 
experimental structure (Figure 3.6). As described above, the overall topology and 
orientation of the loops at the V-C1 interface are quite similar. Thus, the subtle details of 
the interface likely contribute to the observed difference in interdomain angle. 
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 Figure 3.6: The V-C1 interdomain angle is different in the x-ray crystal structure. 
Overlay of ribbon diagrams of the x-ray crystal structure (colored as in Figure 3.1) and 
the VC1 homology model (colored in violet). The two models are overlaid using to the 
C1 domains. Superpositions were made by minimizing the RMSD in Chimera (39). 
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 Analysis of the VC1 homology model suggested numerous side chains from each 
domain pack against each other creating the interface that fixes the orientation of V and 
C1 (Figure 2.12). The V-C1 interface in the x-ray crystal structure shows neither the three 
amino acid linker nor the same dense packing of side chains as seen in the homology 
model. Specifically, the buried surface area is 300 Å2 in the x-ray crystal structure 
compared to 500 Å2 in the homology model. Additionally, both Tyr118 and Gln119 show 
β-sheet hydrogen bonding patterns within the V and C1 domains respectively (Figure 
3.7A). Therefore, there is no linker between V and C1 in the x-ray crystal structure. 
 Despite the absence of intervening residues, it is important to characterize the 
interface between V and C1. Two interdomain contacts were identified by selecting a 
zone of 3.5 Å from all atoms in the V and C1 domains. The first is packing of Pro215 
side chain atoms from the C1F-G loop with the side chain of Tyr118 (Figure 3.7B). The 
second is a potential hydrogen bond between a carboxylate oxygen atom of Glu94 in the 
V domain and the hydroxyl hydrogen on Tyr150 in the C1 domain (Figure 3.7B). 
Notably, Glu94, Tyr118, Tyr150, and Pro215 are absolutely conserved across species 
supporting their functional role in aligning V and C1 in a relatively fixed orientation 
(Appendix A). These interdomain contacts in combination with the steric exclusion of 
conformational space cause the two domains to tumble together in solution.  
Figure 3.7: Interdomain contacts in the VC1 x-ray crystal structure. (A) Stick representation of backbone atoms. Ala28, Ile30, 
Tyr118, Gln119, and Tyr150 are colored according to atom type (C, grey; N, blue; O, red). Potential hydrogen bonds are shown as 
thin cyan lines. (B) Ribbon diagram of VC1 showing the V domain colored in red and the C1 domain colored in blue. Side chain 
atoms from the V domain (Glu94 and Trp118) and the C1 domain (Trp150 and Pro215) are colored as black sticks. The potential 
hydrogen bond between a carboxylate oxygen of Glu94 and the hydroxyl hydrogen of Try150 is shown as a thin cyan line. 
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Summary 
 Determining the high resolution x-ray crystal structure of VC1 provided useful 
insight into the function of RAGE as a signaling molecule. Aside from minor differences 
in the topology of C1, analysis of the structure confirmed hypotheses generated in 
Chapter II from homology modeling about the quaternary structure of sRAGE. Clearly, 
there is an interface (albeit small) between the V and C1 domains that enforces the 
structural integration of the two domains. This interface is stabilized by packing and 
hydrogen bonding of side chain atoms (Figure 3.7B). The lack of intervening residues 
between the two domains also serves to inhibit relative mobility through steric limits on 
the relative positioning of the two domains. Our ability to optimize construct lengths 
based on accurate knowledge of the structure could dramatically aid in future 
biochemical and structural studies. In addition, the structural studies presented in this 
chapter and in Chapter II set the stage to study RAGE-ligand interactions, which are 
presented in the next chapter. The implications and broader conclusions towards receptor 
signaling drawn from the knowledge of VC1 behaving as an integrated structural unit are 
presented in Chapter V. 
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CHAPTER IV 
 
LIGAND BINDING TO SRAGE 
 
 
Introduction 
 S100s are EF-hand containing Ca2+-binding proteins known to have both 
intracellular and extracellular functions (121). As described in Chapter I, S100 proteins 
typically bind to short α-helical peptide segments of their target protein. RAGE is a 
member of the immunoglobulin (Ig) superfamily containing three predicted Ig-like 
domains in its N-terminal ligand binding region (1). Since both the x-ray crystal structure 
of VC1 described in Chapter III and sequence analysis of C2 suggest all β-sheet 
secondary structure, the recognition of RAGE by S100 proteins will either use a novel 
mechanism for binding or induce significant structural changes in RAGE. 
 N(epsilon)-(carboxymethyl)lysine (CML) is a well characterized advanced 
glycation end product (AGE) and a specific, high affinity (KD ~76 nM) ligand for RAGE 
(122). CML is a small AGE moiety characterized by a charge reversal on lysine side 
chains suggesting electrostatics play an important role in recognition by RAGE (Figure 
1.2). CML represents approximately 30% of AGEs in diabetic blood plasma (123). 
Therefore, knowledge of RAGE recognition of CML could provide structural information 
crucial to designing antagonists to lessen the complications of diabetes. 
 While affinities have been estimated for many RAGE ligands, little information is 
available on which Ig domains are used in binding. Only the V domain has been 
implicated in direct binding to CML (122). While S100A12 has been shown to bind 
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RAGE with low nM affinity (43), similar measurements have not been made for S100B. 
In this chapter, the limited proteolysis experiments described in Chapter II are extended 
to gain insight into the domain specificity of S100B binding to sRAGE. S100B was 
chosen due to the large amount of structural information available including complete 
backbone assignments from numerous NMR structures in both apo- and Ca2+-loaded 
states in addition to multiple ligand-bound states, e.g. (124). This information allowed 
preliminary characterization of S100B complexes using NMR. Binding affinities were 
estimated between S100B and sRAGE using surface plasmon resonance. SPR 
experiments were performed by Estelle Leclerc and Dr. Guenter Fritz. Lastly, chemical 
shift perturbation experiments were performed in attempt to map the interaction between 
CML and sRAGE. The summary of these data are combined with the structural 
characterization to generate hypotheses about multiligand receptor activation. 
 
S100B Binding Induces Structural Change in sRAGE 
 Having established limited proteolysis conditions for sRAGE and the six domain 
constructs, proteolysis experiments could be used to characterize the interaction of S100B 
with RAGE. Initial studies with wild-type S100B led to disulfide cross-linking between 
S100B and the V domain. While the S100B-sRAGE disulfide cross-linking could be 
reversed by addition of DTT, the reducing agent also caused the cleavage of the disulfide 
bond essential to maintain the structure of V (Figure 2.2). Consequently, a series of three 
Cys→Ser mutants in S100B were prepared (C68S, C84S, C68S/C84S) and purified. 
Analysis of the V construct in the presence of the three mutants by SDS-PAGE under 
non-reducing and reducing conditions confirmed that the reactive cysteine was Cys84, so 
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the C84S mutant was used for all further experiments (Figure 4.1). Notably, this cysteine 
to serine mutant was shown previously to be functional (125). 
 
 
Figure 4.1: Cys84 of S100B covalently attacks the V domain disulfide bond. Non-
reducing SDS-PAGE of S100B Cys→Ser mutants in the presence of V. Lane 1, 
S100B(C84S). Lane 2, S100B(C68S). Absence of bands at indicated arrow positions and 
the presence of high molecular weight aggregates indicate covalent aggregation. 
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 Studies of isolated sRAGE showed that trypsin digestion results in complete loss 
of the intact protein within 4 hours (Figure 2.3A). The overall rate of digestion was 
similar in the presence of Ca2+-S100B (Figure 4.2A), although sRAGE was slightly, yet 
reproducibly, better protected in the presence of S100B than in isolation. As expected, 
this observation was dependent on the presence of calcium. Interestingly, the 25 kDa 
band identified as VC1 in the digestion of free sRAGE was completely absent when 
Ca2+-S100B was present (Figure 4.2A, see arrows). This observation was also calcium-
dependent. While protection from proteolysis is more common, an increased rate of 
proteolysis is also possible when structural perturbations are induced by protein-protein 
interactions. The expedited degradation of the VC1 fragment in sRAGE digests could not 
be explained by the presence of a contaminating protease in our S100B sample since this 
would be inconsistent with the observation that degradation of the intact protein was 
slowed. Thus, the interaction between Ca2+-S100B and sRAGE appears to cause a 
conformational change in the VC1 region of sRAGE that enhances proteolysis by trypsin. 
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 Figure 4.2: S100B binding causes a conformational change in sRAGE. Protease 
protection of sRAGE by Ca2+-S100B. Reducing SDS-PAGE of sRAGE (A) and VC1 (B) 
incubated with trypsin in the absence (left) or presence (right) of Ca2+-S100B. Solution 
conditions were the same in the absence and presence of S100 protein and are described 
in Chapter VI. Filled arrows mark the S100B band. Open arrows mark the stable 25 kDa 
VC1 fragment most affected by S100B binding. Time points are given in minutes. 
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 To corroborate these findings, the experiments were repeated with the various 
sRAGE domain constructs. Much like intact sRAGE, isolated VC1 was reproducibly 
protected in the presence of Ca2+-S100B, but the 25 kDa fragment was very rapidly 
degraded (Figure 4.2B). The isolated V domain was also more rapidly degraded in the 
presence of Ca2+-S100B consistent with the increased rate of proteolysis on VC1 (Figure 
4.3). Corresponding experiments with C1C2 and isolated C1 and C2 revealed no 
interaction with Ca2+-S100B as the C1 domain continues to be degraded extremely 
rapidly under all conditions, and the C2 domain remains totally resistant to digestion by 
trypsin under these experimental conditions. Together, these limited proteolysis results 
indicate that the interaction of S100B with RAGE is calcium-dependent and localized 
primarily to the V domain. 
 
 
Figure 4.3: S100B binding is localized to the V domain. Protease protection of RAGE-V 
by Ca2+-S100B. Reducing SDS-PAGE of V domain incubated with trypsin in the absence 
(left) or presence (right) of Ca2+-S100B. The band migrating at ~ 6 kDa is a single S100B 
polypeptide. Solution conditions were the same in the absence and presence of S100 
protein. Time points are given in minutes. 
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NMR Characterization of S100B Binding to sRAGE 
 S100B-sRAGE binding was further investigated using NMR spectroscopy. As 
mentioned in Chapter II, the NMR chemical shift is exquisitely sensitive to the local 
chemical environment and can be used to monitor structural changes induced by ligand 
binding. The optimal conditions for acquiring NMR spectra for sRAGE required the use 
of high ionic strength buffer (>250 mM NaCl). However, the complex could be formed 
successfully only at lower ionic strength (<100 mM NaCl), conditions under which, 
remarkably, free sRAGE had only very limited solubility. The fact that binding of S100B 
solubilized sRAGE is, in and of itself, confirmatory evidence of an interaction between 
S100B and sRAGE. The 15N-1H HSQC and TROSY-HSQC spectra of 2H,15N-sRAGE in 
the presence of excess Ca2+-S100B showed only peaks arising from C2 (Figure 4.4). The 
absence of signals from VC1 is interpreted as a result of binding of S100B to one or both 
domains, since it is expected that a large molecular complex is formed containing an 
S100B dimer and presumably two sRAGE molecules, although no conclusive 
experimental evidence is currently available. The observation of C2 signals, completely 
unperturbed, indicates that C2 retains its structural independence from the rest of the 
complex. 
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 Figure 4.4: C2 retains its structural independence when in complex with Ca2+-S100B. 
15N-1H HSQC spectra are overlaid for either protonated (black) or perdeuterated (red) 
sRAGE in the presence of S100B. Some of the red contours that do not have 
corresponding black contours are excessive noise due to the extremely low protein 
concentrations used in that sample (~ 40 µM). 
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 To complement the study of S100B binding to sRAGE, NMR was used to probe 
the interaction with the V and VC1 constructs. In titrations of 15N-enriched V and VC1 
with Ca2+-S100B, a uniform decrease in signal intensity was observed for all except ten 
of the crosspeaks in VC1 as S100B was added (Figure 4.5). The few VC1 signals that 
remained observable had chemical shifts and linewidths consistent with being part of the 
flexible, unstructured tail at the C-terminus of this construct. Control experiments on 
C1C2, C1, and C2 showed no changes in 15N-1H HSQC spectra induced by the presence 
of Ca2+-S100B. Thus, consistent evidence was obtained for relatively strong interaction 
of S100B with sRAGE, and that the V domain is clearly involved. 
Figure 4.5: Both domains of VC1 are broadened by S100B. Shown are 15N-1H HSQC spectra of VC1 in the absence (left) or presence 
(right) of a 2:1 stoichiometric amount of VC1 to S100B dimer. 
 
86 
S100B Binds to RAGE with nM Affinity 
 A detailed analysis of surface Plasmon Resonance (SPR) measurements for 
S100B binding to immobilized sRAGE revealed affinity constants in the nM range 
(Estelle Leclerc, Guenter Fritz, Claus Heizmann, in preparation). SPR was used here to 
further probe the binding of S100B to sRAGE using VC1, V, and C2 constructs. In these 
experiments, binding was observed to VC1 and V, but no interaction with the C2 domain 
was detected. 
 Typical S100B binding curves for VC1 and V chips are shown in Figure 4.6. In 
the case of VC1, the data were fit with the parallel reaction model for heterogeneous 
ligand: 
A + B1 ↔ AB1 and A + B2 ↔ AB2 
where one analyte molecule (A = S100B) can bind independently to two ligand 
molecules B1 or B2 (VC1) with KD1 the dissociation constant of the first equilibrium, and 
KD2 the corresponding parameter for the second event. This analysis gave two binding 
constants: KD1 = 11.1 nM and KD2 = 244 nM (Figure 4.6A). These results are largely 
consistent with the affinity determined for intact sRAGE. The S100B binding curves for 
the V domain (Figure 4.6B) were also fit with the parallel reaction model. Fitting of the 
binding data resulted in KD1 = 550 nM and KD2 = 470 nM. Although the quality of the fit 
for KD1 was much poorer for VC1 than for the isolated V domain, the affinity of S100B 
for the immobilized VC1 construct is clearly higher than that for the isolated V domain. 
In summary, these data indicate that S100B binds to the V domain of sRAGE and while 
V contains a site sufficient for binding of S100B dimers, additional contributions are 
made either directly or allosterically by the C1 domain. 
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 Figure 4.6: SPR binding of S100B to sRAGE domains. Representative binding 
sensorgrams for S100B binding to (A) immobilized VC1 and (B) immobilized V. 
Injection concentrations from top to bottom are 12.6 µM, 6.3 µM, 3.15 µM, and 1.57 µM 
for both (A) and (B). 
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CML Binding to RAGE 
 CML modified human serum albumin was first shown to be a ligand of RAGE by 
Kislinger and coworkers in 1999 (122). However, isolated CML was unable to compete 
for binding to CML-HSA. More recently, Ostendorp and coworkers showed direct 
binding of purified CML to recombinant sRAGE purified from yeast suggesting isolated 
CML could be used for chemical shift mapping studies (109). In order to determine if 
NMR could be used to monitor the binding of CML to sRAGE and its domain constructs, 
initial titrations were performed using 15N-enriched V. Although reasonably strong 
binding has been reported, titration points up to 20 times the concentration of V domain 
failed to produce any observable NMR chemical shift perturbations (Figure 4.7). Several 
experimental conditions were tested and varied in ionic strength (0-300 mM NaCl), 
buffer composition (Tris-HCl, phosphate), and pH (6.0-7.5) with identical results. 
Repeating these CML titrations using 15N-enriched VC1 provided very similar results. 
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 Figure 4.7: CML titration into 15N-enriched V. Overlay of 15N-1H HSQC spectra of 
isolated V domain in the absence (black) and presence (red) of 20x excess CML. 
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 A separate analysis was then performed where a 1H spectrum of CML was 
observed as unlabeled V was titrated. This experiment would take advantage of the fact 
that the signals arising from CML would be much more narrow and intense than signals 
arising from V. However, no significant changes in the linewidth or chemical shift of 
CML peaks were observed (Figure 4.8). Slight intensity changes are observed on CML 
peaks between 1.0 and 2.0 ppm, presumably arising from the additive effect of signals 
from the V spectrum (Figure 4.8). Since monitoring by NMR proved unsuccessful, 
alternative strategies were attempted to characterize CML binding. Titrations were 
performed monitoring either tryptophan fluorescence or heat evolution by isothermal 
titration calorimetry. However, neither experiment produced a binding curve that would 
be consistent with the strong binding reported by Ostendorp and coworkers (109). The 
interpretation of these results is that CML binds dynamically to RAGE, i.e. the small 
ligand associates tightly with the receptor overall but interacts with multiple binding 
sites. An elaboration of this concept is described in Chapter V. 
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 Figure 4.8: CML is unperturbed in the presence of the isolated V domain. Overlay of 1H 
NMR spectra of CML in the absence (black) and presence (red) of isolated V domain.  
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Summary 
 The interaction of S100B with sRAGE was characterized using a protease 
protection assay. The proteolysis data suggest S100B binding is localized primarily to the 
V domain since no interaction is observed to isolated C1 or C2. However, C1 does play a 
secondary role, either through stabilization of V or an allosteric structural effect. In 
addition, binding appears to cause a conformational change in sRAGE as evident by the 
increased rate of trypsin digestion. 
 Attempts to use NMR chemical shift perturbation assays to map binding surfaces 
between S100B and sRAGE were plagued by complications. The one fact that remained 
clear was the C2 domain remained flexible in the complex of S100B and sRAGE. Hence, 
these results support the model for sRAGE structure described in Chapter II and suggest 
C2 remains structurally independent during S100B binding. 
 Binding of S100B to sRAGE was quantified and found to be in the range of nM 
affinity. An important aspect of these experiments was the structural integration of the V 
and C1 domains. Specifically, S100B binds to VC1 with V as the major interaction site. 
Consistent with the results from limited proteolysis experiments, binding to isolated V 
occurs with much weaker affinity than to tandem VC1, presumably due to the reduced 
stability of V in the absence of C1. Thus, integration of V and C1 is necessary for both 
structural integrity and ligand binding. The implications and broader conclusions of these 
data are discussed in Chapter V. 
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CHAPTER V 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Implications and Conclusions 
 
The Modular Structure of sRAGE 
 The generation of efficient protein expression systems was critical to the studies 
reported in this dissertation and opens the door to use these reagents to probe RAGE 
function. Biophysical and structural characterization showed that C2 exhibits the 
characteristics of a stable well-folded structural domain. In contrast, V and C1 do not 
form fully independent structural domains but rather behave as an integrated structural 
unit. Thus, in the model for the structure of sRAGE (Figure 5.2), the C2 domain retains 
significant structural flexibility, whereas V and C1 are structurally interdependent. 
There is ample evidence for V and C1 forming an integrated structural unit. From 
the initial stages of analysis, the C1 domain in particular appeared to be rather unstable 
without V. Many constructs of C1 and C1C2 were designed in the attempt to obtain 
expression of soluble protein in E. coli and it was only after extensive optimization that 
even limited success was obtained. Even the most stable of the C1 constructs exhibits 
clear signs of heterogeneity, is digested rapidly in limited proteolysis experiments, and 
readily degrades over time. The 15N-1H HSQC spectrum of our optimized C1 construct 
contains some signals with chemical shift dispersion, but the existence of a large excess 
of peaks with variable intensities and the crowding of many signals in the central region 
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suggests that the isolated domain is structurally heterogeneous and in fact a significant 
portion of this construct may be unstructured. The isolated V domain is more stable and 
structured than isolated C1. For example, it was digested more slowly by trypsin and the 
15N-1H HSQC spectrum of V has far fewer peaks than C1, although it too shows signs of 
conformational heterogeneity. Importantly, both the V and C1 domains become 
significantly more stable to trypsin digestion and more structurally homogeneous when 
they are linked to each other in the VC1 and sRAGE constructs. 
 The x-ray crystal structure of VC1 allows refinement of the model for the 
structure of sRAGE. Trp230 is the C-terminal residue participating in secondary structure 
in C1. Two potential hydrogen bonds, Glu231 (side chain oxygen) to Gly199 (amide 
proton) and Pro232 (carbonyl oxygen) to Arg198 (side chain N-H), could effectively 
shorten the C1-C2 linker. However, crystal packing involving the C-terminal extension 
could stabilize these hydrogen bonds which may not be highly populated in solution. The 
homology model for C2 shows the first amino acid involved in β-sheet hydrogen bonding 
is Pro234 (Figure 5.1). Thus, the aggregate data suggest the C1-C2 linker is three 
residues (ignoring side chain contacts described above). 
 Therefore, it is intriguing to understand the structural determinants of C2 
flexibility. As in all Ig folds the region of highest variability is between the c and e 
strands. C2 shows a truncation in sequence between strands c and e that contains a short 
strand (c') and a linker that is nearly perpendicular to the plane of the β-sandwich (Figure 
5.1). This amounts to a reduction in the number of interstrand loops in proximity to the 
C1-C2 linker. In fact, analysis of the C2 homology model actually shows characteristics 
of an S-type Ig fold (120). The C1 domain has three large loops directly facing the V 
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domain (Figure 3.1) while the C2 domain only has two loops directly facing the C1 
domain. Thus, it is possible that the lack of side chain density and surface 
complementarity at the C-terminal face of C1 and the N-terminal face of C2, despite the 
likelihood that the C1-C2 linker is ~3 residues, enables the C2 domain to remain 
structurally independent of VC1. 
Figure 5.1: Homology model of C2 suggests S-type Ig fold. (A) Ribbon diagram of the homology model of C2 with each strand 
labeled according to the topology diagram in (B). The N- and C-termini are labeled. The B-C and F-G loops, in spatial proximity to 
C1, are near the N-terminus. 
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 There are likely two functions to Ig interdomain linkers. One is to enable non-
linear interdomain packing, as in the case of the Fab light chain used to model VC1. A 
short linker like in VC1 promotes a near linear interdomain angle (Figure 3.1). Increasing 
the linker length could therefore enable an increased angle between the two domains. In 
addition, longer linkers could allow conformational changes when ligand binds. The 
absence of a linker in VC1 will likely inhibit significant conformational changes upon 
ligand binding. Thus, the conformational change in VC1 induced by S100B binding that 
is inferred from protease protection assays (Chapter IV) may be localized to interstrand 
loops and not a reorientation of the interdomain angle. A second function for interdomain 
linkers is to allow Ig domains to remain structurally independent of each other. This 
seems to be the case for C2, where structural flexibility is apparently enabled by in the 
C1-C2 linker. 
 The x-ray crystal structure also helps to explain several key experimental 
observations. For example, the observation of an ~2 kDa truncation of VC1 in limited 
proteolysis experiments on the RAGE(23-243) VC1 construct can be correlated with the 
prediction of an ~10 residue unstructured C-terminal tail. This also explains the ~10 
extremely sharp peaks observed in the HSQC spectrum of V, which the structure predicts 
arise because the V construct (23-132) extends 14 residues beyond the predicted C-
terminus of the domain. The NMR signals from these sharp resonances change 
significantly when they are incorporated into the VC1 construct. This can be attributed to 
their shift from being unstructured in isolated V to participating in β-sheet secondary 
structure when the C1 domain is included (Figure 2.11). This has been confirmed through 
the generation of new VC1(23-233) and V(23-119) constructs whose 15N-1H HSQC 
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spectra show retention of the overall fold while lacking the ~10 sharp peaks (Appendix 
C). The x-ray crystal structure also suggests at least one large C1 sidechain (Tyr150) with 
significant hydrophobic character could be involved in interactions with V; it is possible 
the exposure of this residue to solvent could be the source of heterogeneity and/or 
instability. Hence, the overall conclusion supported by the biochemical and structural 
data is that V and C1 form an integrated structural unit that is fully independent of C2. 
Figure 5.2: Model for the structure of sRAGE. This model was created by joining the x-ray crystal structure of VC1 (colored with the 
V domain in red and the C1 domain in blue) with a homology model of C2 (violet). The three residue C1-C2 linker is connected to 
scale and colored black. While the image is static, the C1-C2 linker has structural flexibility and the C2 domain could adopt many 
different orientations with respect to VC1. 
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Implications for Ligand Binding 
 The modular structure of sRAGE differs from the initial assumption based on 
sequence analysis that there would be three independent domains. It has been proposed 
that over the course of evolution, Ig-like superfamily proteins developed a modular 
assembly of domains. Ideally, each domain provides unique functionality, which results 
in the generation of proteins that can respond to multiple ligands (126). Central to this 
hypothesis is the concept of one-domain, one-ligand. However, RAGE does not seem to 
fit this paradigm as all of its ligands identified to date, including S100B, are found to 
interact with the N-terminal V domain of the protein. In this respect, a recent publication 
suggesting S100A12 binds to the C1 domain stands out as unusual (127). However, the 
conclusions drawn in that study were all based on use of a C1C2 construct with an N-
terminus at Ala130. The x-ray crystal structure suggests this construct eliminates the 
entire first β-strand of C1, which is anticipated to be highly destabilizing. Indeed the 
results in this dissertation show that C1 does not maintain a proper fold in the absence of 
V. Since C1 requires V for full stability and structural integrity, the construct used in that 
study may well be structurally unstable and might exhibit aberrant function. The 
conclusion that S100A12 binds to the C1 domain may need to be re-examined with 
alternate reagents and these issues in mind. 
 The nM dissociation constant (KD) determined for S100B binding to sRAGE and 
VC1 is consistent with values published for other sRAGE ligands. Dissociation constants 
of 60 nM, 6.4 nM, 56.8 nM, and 91 nM have been reported for AGE-BSA, amphoterin 
(HMG1), amyloid-β peptide, and EN-RAGE (S100A12), respectively (1, 27, 40, 43). 
Recently, Wilder and coworkers showed binding of a peptide from the V domain 
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(residues 42-59) to S100B and reported a KD of 11 µM (128). Notably, that result is 2-3 
orders of magnitude weaker than the KDs for other RAGE ligands. The authors proposed 
an important role for Trp51 in sRAGE for binding of S100B (128). In the x-ray crystal 
structure of VC1, this residue is buried in the hydrophobic core, which implies it is not 
involved in S100B binding. The structure predicts residues adjacent to Trp51 that are part 
of one or more loops are much more likely to contribute to S100B-RAGE binding. This 
hypothesis is consistent with our results on the binding of S100B to the V domain, which 
revealed KDs of 550 nM and 470 nM. Although clearly weaker than the affinity for VC1 
and sRAGE, binding of the V domain is much stronger than for the V(42-59) peptide. 
Nonetheless, the constructs based on V alone lack critical binding elements relative to 
VC1, which weakens the interaction with S100B. 
 Attempts to monitor the interaction between synthesized CML and bacterial 
sRAGE did not produce observable chemical shift perturbations. One possible 
explanation is that native RAGE is N-glycosylated at two potential sites in the V domain, 
but the bacterially expressed proteins are not glycosylated. Favorable effects from 
glycosylation on solubility and stability are anticipated, but the effect on the structure of 
folded proteins is generally believed to be quite small. There is significant evidence in 
support of the latter in the case of RAGE. First, RAGE can be readily deglycosylated 
with Peptide N-Glycosidase F. This indicates that the carbohydrates are solvent 
accessible, which in turn implies they do not interact significantly with, or alter the 
structure of, the folded protein domains (129). Second these authors showed that RAGE 
deglycosylation has a minimal effect on binding of the ligands amphoterin and AGE-
BSA. Third, similar observations have been recently reported for the bacterially 
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expressed protein (107). While bacterial sRAGE was capable of binding AGE-BSA 
(heterogeneous AGEs), Wilton and coworkers reported that bacterial sRAGE did not bind 
CML-BSA (107). The direct binding of synthesized CML to yeast sRAGE (109) 
therefore suggests some glycosylation may be necessary for maximal binding affinity. 
 An alternate explanation is that CML binds dynamically with high affinity and 
interacts via multiple binding sites. In this model, the highly acidic CML binds to the 
large basic surface of the V domain in a non-specific manner. The small size of CML 
allows it to interact at multiple sites on V and the high net positive charge of the surface 
ensures that CML does not effectively diffuse away allowing it to switch to a different 
site. The intrinsically dynamic nature of electrostatic-based ligand binding would 
minimize the entropic penalty associated with binding thereby enabling an intrinsically 
weak association for specific sites (at the microscopic scale) to be effective at providing 
the much stronger affinity observed overall at the macroscopic level. This is consistent 
with the lack of precise chemical shift perturbations and saturation of binding described 
in Chapter IV. Nonetheless, the accumulated evidence supports the notion that these 
constructs serve as valid models for the study of sRAGE structure and ligand binding. 
 
Implications for RAGE Signaling 
 The characteristics of sRAGE structure relate to its mechanism of signaling. The 
results show that the C2 domain of RAGE has significant structural flexibility from the 
VC1 region. Specifically, NMR spectra of sRAGE-S100B complexes show C2 is flexibly 
attached to VC1 and remains unperturbed when S100B binds to VC1 suggesting there is 
no signal passed directly between VC1 and C2. Hence, a mechanism where ligand 
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binding in the VC1 region is transduced via C2 and the transmembrane helix to the 
intracellular domain is not anticipated for RAGE. 
 As described in Chapter I, RAGE belongs to a class of receptors that contain a 
single transmembrane helix and signal through kinases. While most of these receptors 
dimerize, the degree of oligomerization varies for different members of this class. In the 
case of EPOR, the D1 and D2 domains form an integrated structure that dimerizes in an 
autoinhibitory orientation (Figure 1.7). Ligand binding causes a conformational change in 
the interdimer angle, which is believed to promote signaling by enabling trans-
phosphoryation of the kinases bound to the intracellular domain (98, 99). GHR also exists 
in an autoinhibited state but dimerizes via its transmembrane helix (Figure 1.7). Ligand 
binding to GHR results in rotation of the transmembrane helix, which in turn is 
transmitted to the intracellular domain because all of the structural elements are coupled 
(104). Thus, ligand binding causes reorientation into an architecture where trans-
phosphorylation can occur. The flexibility between the VC1 and C2 domains implies 
neither of these allosteric mechanisms could be operative in the case of RAGE. 
 Signaling via RAGE occurs through the ERK1/2 kinase. Remarkably, the 
intracellular (IC) region of RAGE is very small and characterization of this region by CD 
and NMR showed it has little persistent secondary or tertiary structure (Figure 5.3). 
Despite being so small and unstructured, this domain binds to both phosphorylated and 
unphosphorylated ERK1/2 in a ligand-dependent manner (51). The absence of any 
structure in the intracellular domain implies the most likely mechanism for RAGE 
signaling is via ligand-induced oligomerization and resultant localization of multiple 
kinase molecules. A proposal for RAGE signaling through oligomerization has been 
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reported based on the crystal structure of S100A12 (85). In this model three dimers (six 
subunits) of S100A12 bind three molecules of RAGE, but the mechanistic implications 
for RAGE are not described. 
Figure 5.3: Structural characterization of the intracellular domain (IC) of RAGE. (A) SDS-PAGE showing purification of RAGE-IC 
(residues 364-404). Lane 1, after Ni-affinity. Lane 2, after thrombin cleavage. Lane 3, after SourceQ. Aberrant protein band migration 
is likely due to high acidic pI of the intracellular domain. (B) CD spectrum of RAGE-IC. (C) 15N-1H HSQC of RAGE-IC acquired at 
500 MHz and 25 °C in 20 mM Tris-HCl, 10 mM CaCl2 at pH 7.0. 
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  Figure 5.4 shows schematic diagrams of simple models for RAGE signaling that 
incorporate the multiligand functionality of RAGE, receptor oligomerization, and the 
flexibility of the C1-C2 linker. In particular, free rotation around the C1-C2 linker allows 
the VC1 domains to utilize different surfaces to interact with different ligands without 
disrupting the orientation of the signaling components (C2, transmembrane helix, and/or 
intracellular domain). Figure 5.4A shows two hypothetical signaling complexes where 
ligand-induced dimerization occurs on different VC1 surfaces. In this scenario, 
unliganded RAGE would be autoinhibited, perhaps due to electrostatic repulsion of the 
highly charged intracellular kinase binding domains. Ligand binding dimerizes the 
receptor and increases localization of ERK1/2 to initiate the signaling cascade. This 
model could also be adapted if it turns out that RAGE dimerizes via the transmembrane 
helix (or via as yet uncharacterized ligands). Figure 5.4B shows a schematic diagram of 
one such scenario where ligand binding leads to formation of a network of RAGE 
receptors. One important feature of this model is the VC1 domains would still have 
rotational freedom to present different binding surfaces for different ligands. Thus, a 
ligand-induced network of RAGE receptors is formed, increasing the localization of 
ERK1/2 to promote signaling. 
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Figure 5.4: Models for ligand-induced activation of RAGE through oligomerization. (A) 
Schematic diagram showing ligand-induced dimerization is possible using different 
surfaces of VC1. (B) Schematic diagram of ligand-induced network of RAGE dimers. 
The ligand is shown as a green or orange circle. Coloring for sRAGE domains is the 
same as in Figure 1.1. 
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  These data and observations in the literature such as the analytical 
ultracentrifugation study by Wilton and co-workers (107) suggest the sRAGE molecule 
in isolation is monomeric. These results in turn point strongly to a ligand-mediated 
oligomerization mechanism for RAGE signaling. This hypothesis is supported by data 
from a variety of RAGE splice variants including a variant lacking the intracellular 
domain, which was found to be dominant-negative in vivo (23, 130). Another splice 
variant lacking a portion of the V-domain was not dominant-negative, presumably 
because ligand binding was weakened but not abolished (131). Determination of the 
oligomeric states of sRAGE-ligand complexes and the natural oligomeric state of the 
unliganded full receptor will be required in order to develop an understanding of the 
molecular basis for RAGE signaling. These and other future directions are proposed in 
the following section. 
 
Future Directions 
 
High Resolution Structure of the C2 domain 
 The studies in this dissertation describe the quaternary structure of sRAGE which 
includes a high resolution x-ray crystal structure of the VC1 region. However, the high 
resolution structure of C2 is still lacking. The homology model described above suggests 
C2 is an S-type Ig domain. Given the important differences between the experimental and 
modeled structure of VC1, determination of the C2 structure is warranted. However, 
numerous attempts at crystallization have failed to produce diffraction quality crystals. 
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 The boundaries for this construct appear to be based on the homology model, so no 
simple solution to crystallization comes to mind. 
 In contrast, the prospects for structure determination by NMR spectroscopy are 
quite promising. The 15N-1H HSQC spectrum of C2 shows excellent chemical shift 
dispersion and resonance linewidths (Figure 5.5). In fact, nearly complete 13C, 15N, and 
1H backbone resonance assignments have been made for C2 using standard 3D triple 
resonance experiments including HNCA, HN(CO)CA, CBCA(CO)NH, and HNCACB 
(Figure 5.5). The few incomplete assignments arise from two serine and two leucine 
residues (Figure 5.5, Appendix D). All four of these residues are flanked by prolines at 
both the N- and C-terminal positions. Thus, standard triple resonance experiments cannot 
differentiate the two serines (and likewise the two leucines) from each other. Analysis of 
NOESY and TOCSY spectra should enable completion of these assignments. Hence, 
NMR solution structure determination is quite feasible. Key issues that remain to be 
resolved are the exact topology of C2 and the precise length of the C1-C2 linker, both of 
which are of vital importance to understand signaling mechanisms. 
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Figure 5.5: 15N-1H HSQC spectrum of C2 with backbone assignments. The underlined 
residues in the following sequence have been assigned: 
GSHMLEEVQLVVEPEGGAVAPGGTVTLTCEVPAQPSPQIHWMKDGVPLPLPPSP
VLILPEIGPQDQGTYSCVATHSSHGPQESRAVSISIIEPGEEG
A complete list of backbone 1H, 15N, and 13C chemical shifts is presented in Appendix D. 
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 The Oligomeric State of Intact RAGE 
 All analyses thus far have indicated that sRAGE exists primarily in a monomeric 
structural state (1, 107, 109, 132). The data in this dissertation is fully consistent with 
these studies. In a critical functional assay using intact RAGE, deletion of the 
cytoplasmic domain leads to a dominant-negative receptor (dnRAGE), which clearly 
implies RAGE functions in an oligomeric state. Thus, the natural oligomeric state of the 
intact receptor is critical for understanding the structural mechanisms of autoinhibition 
and activation. 
 Numerous approaches can be made to address this problem. RAGE constructs 
with different affinity tags can be cotransfected in cultured cells and analyzed with and 
without ligand stimulation. Immunoprecipitation with one antibody followed by detection 
with the other antibody could assess natural oligomerization and ligand dependence of 
oligomerization since physical contact between of the differently tagged proteins would 
be required for coimmunoprecipitation. Additionally, fusions to fluorescent probes would 
allow FRET experiments to assess both oligomerization and relative proximity of the 
intracellular domains in addition to ligand-induced changes. Fascinating experiments 
have been performed on EPOR using dihydrofolate reductase subunits to show both 
unliganded dimerization and a ligand-induced structural change (100). 
 The experiments described above, however, would not establish the structural 
features of RAGE that promote oligomerization. Assays have been developed in E. coli 
to assess the potential for transmembrane helices to oligomerize. One assay called 
TOXCAT utilizes a transcriptional activator that is dependent on dimerization to confer 
antibiotic resistance to chloramphenicol (133). The transformed plasmid encodes for 
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 periplasmic localized MBP, fused to the transmembrane helix sequence in question, 
which in turn is fused to the transcriptional regulator. Thus, not only can this assay 
establish if the transmembrane helix (RAGE-TM) dimerizes, but it can be used to assay 
mutations to disrupt oligomerization. Finally, these mutations can be reincorporated into 
cell based assays to assess the functional importance of RAGE-TM oligomerization. This 
information is critical to determine if oligomerization is necessary and sufficient for 
activation or if specific structural orientations are required. 
 A separate question involving receptor oligomerization is generated by the 
observation that ERK1/2 coimmunoprecipitates with RAGE and that the interaction is 
ligand-dependent (51). This implies either a direct structural change or oligomerization is 
necessary to present a binding surface for the kinase to interact with the intracellular 
domain (RAGE-IC). While the interaction in cell culture was ligand-dependent, purified 
RAGE-IC was also able to bind ERK2 (ERK1 was not tested). However, it is of note that 
the approach for purification and immobilization in the pull down assays involved GST. 
GST is a known dimer and the specific plasmid used has a significant linker that could 
allow the fused RAGE-ICs to come into proximity. This interaction should be tested in 
vitro using purified proteins with no tag or with fusion proteins that are monomeric. 
Differences in binding to monomeric RAGE-IC vs. GST-fused RAGE-IC could provide 
insight into mechanisms of receptor activation, especially if a dimeric GST is required for 
interaction. Receptor oligomerization is also discussed later with respect to the 
stoichiometry of sRAGE-ligand complexes. 
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 Variable RAGE Surfaces Used in Ligand Recognition 
 RAGE is activated by structurally diverse ligands, which suggests that different 
surfaces of RAGE extracellular domain are utilized. Multiple approaches can be used to 
determine the molecular details of protein-protein interactions including x-ray 
crystallography. In fact, preliminary crystals of the S100B-VC1 complex have been 
obtained by Dr. Guenter Fritz and diffract to ~7 Å. These crystals may be improved using 
optimized constructs based on the x-ray crystal structure presented above (Appendix C). 
Nonetheless, it is essential to pursue structure determination of this complex or use other 
techniques to elucidate the surface residues necessary for binding because the details of 
ligand recognition are central to the hypothesis introduced above that the flexibility of the 
C1-C2 linker is required to allow activation by different ligands. 
 NMR provides an alternative strategy to characterize the structure of the S100B-
VC1 complex. Overcoming the large molecular size and long correlation time is typically 
done using perdeuteration and TROSY (111, 112). However, this system has still been 
difficult to study despite these technical advances, presumably due to non-binary binding 
kinetics (consistent with the complex binding model from SPR data discussed in Chapter 
IV). Therefore, simplifying the analysis by using less direct structure-function strategies 
can be taken to obtain structural insights. 
 For example, one recent study identified a short peptide from the V-domain of 
RAGE that exhibited an 11 µM dissociation constant for binding to S100B (128). An 
S100B consensus binding motif has been previously identified (134) and points to a key 
role for Trp51, whose side chain lies buried in the hydrophobic core of the V domain. 
Therefore, it is possible that surface exposed residues adjacent to Trp51 play a more 
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 important role in interaction with the peptide. Similar approaches involving mutation of 
amino acids with surface exposed side chains (controlling for overall structural integrity) 
can be used to assay whether this segment of the V domain is involved in binding to 
S100B (Figure 5.6). 
 A 34 residue peptide from amphoterin has been shown to bind RAGE (38). Half 
of this peptide lies within the C-terminal α-helix of the second HMG box domain of 
amphoterin (Figure 1.3), with the other half existing in the unstructured C-terminal 
region. This peptide functions as a RAGE antagonist in vitro and in vivo and could be 
used to assess the molecular details of RAGE-amphoterin interaction. Analyzing a 
complex of a peptide and a 15N-enriched protein is typically easier than two intact 
proteins due to smaller changes in the size of and hence the correlation time of the 
complex. 
 Another structure-function study involved the minimal Aβ sequence that shows 
strong affinity for sRAGE. The Aβ sequence is 11 residues in length and encompasses 
positions 25-35 of the canonical Aβ peptide (40). Generally, fibril formation is a slow 
process in the absence of seeding suggesting NMR titrations could be performed, 
especially at lower protein concentrations, taking advantage of the high S/N of 
cryoprobes. This might provide similar information to the above described analysis with 
amphoterin. 
 All information gained from the above experiments would be combined with our 
current knowledge of AGE recognition by RAGE. Yeh and coworkers showed that a 17 
amino acid peptide from the V domain (shown mapped onto the structure of V in Figure 
5.6) is able to compete for binding of CML-HSA (25). However, this finding is 
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 controversial since some studies suggest RAGE binding to CML requires N-
glycosylation (107). Nonetheless, a critical aspect to understanding the structural 
mechanisms of RAGE activation lie in the molecular details of multiligand recognition. 
Therefore a broad approach should be taken utilizing structural techniques in addition to 
carefully controlled functional studies to ascertain these critical pieces of information. 
 
 
Figure 5.6: Regions of ligand recognition by RAGE. Ribbon diagram of the x-ray crystal 
structure of RAGE-V (C1 has been removed for clarity) showing segments implicated in 
ligand recognition. Colored in red is the peptide used to compete for binding to CML-
HSA. Colored in green is the peptide shown to bind in vitro to S100B. Surface exposed 
side chains that could contribute to S100B binding are shown as wires. 
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  Stoichiometries of sRAGE-Ligand Complexes 
 Earlier I proposed experiments to assess the oligomeric state of the intact receptor 
to gain insight into signaling mechanisms. Equally important in receptor signaling are 
changes in oligomeric state caused by ligand binding. In the absence of ligand, the RAGE 
extracellular domain is predominately monomeric as shown by numerous groups in 
addition to the studies described within this dissertation (1, 107, 109, 132). Based on 
structural characteristics of RAGE ligands and cytokine receptors described in Chapter I, 
multiple copies of sRAGE are predicted to be involved in RAGE signaling. Ideally, 
techniques such as gel filtration and light scattering could be useful in this context. 
However, the information from these approaches tends to be incomplete in the absence of 
details on the precise shape of the complex. Ig domains have an elongated structure, a 
property that is further accentuated in tandem constructs like VC1 and intact sRAGE, so 
other complementary experimental approaches are required. For example, analytical 
ultracentrifugation should be the primary technique used to estimate RAGE-ligand 
stoichiometries. A combination of sedimentation velocity and sedimentation equilibrium 
can assess both the molar mass of these complexes and equilibrium dissociation 
constants, respectively. Comparing the stoichiometries of different sRAGE-ligand 
complexes would provide information on potential differences in RAGE activation 
proposed at the beginning of this chapter. 
 
Potential Mechanisms for AutoInhibition of RAGE 
 Preventing the transient activation of a cell surface receptor is important for tight 
regulation of signaling pathways. Autoinhibition of cytokine receptors was described in 
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 Chapter I. In one model, a preformed receptor dimer exists in a fixed orientation that 
requires ligand binding to physically bring the intracellular domains into proximity and 
promote trans-phosphorylation of the associated kinases. In a second model, the 
associated kinases are in proximity in the preformed dimer but are rotated in an 
autoinhibited conformation. 
 A common structural feature within the extracellular domains of cytokine 
receptors, the WSXWS motif (one-letter amino acid code where X is any amino acid), is 
necessary for proper receptor regulation. The crystal structure of IL-4R reveals the two 
Trp side chains from this motif form a tryptophan-arginine zipper as shown in Figure 5.7. 
A recent proposal suggests the WSXWS tryptophan side chains can flip out of the zipper 
and embed in the membrane creating an autoinhibited conformation of the receptor (135). 
Free energies were calculated for solvent exposure of the WSXWS tryptophan side 
chains; the energetic penalty of solvent exposure could be compensated for by the free 
energy gained through membrane interactions. Thus, ligand binding could cause the 
release of the extracellular domain from its interactions with the membrane facilitating 
receptor activation. 
 RAGE does not have a defined tryptophan-arginine zipper; however, RAGE does 
have a number of surface accessible aromatic side chains. Two in particular are Trp61 
and Trp72, of the V domain, whose side chains have 46% and 57% solvent accessible 
surface area, respectively (Figure 5.7). Both residues are 100% conserved across species 
(Appendix A). The functional significance of these surface aromatic side chains can be 
tested with point mutagenesis. Trp→Arg or Trp→Lys mutations could satisfy the 
hydrophobic contacts while placing charged groups at the surface. Mutations in the full 
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receptor can be assayed in cell culture for transient and ligand-induced activation. 
“Leaky” activation of NF-κB in mutant vs. wild-type RAGE would imply a disruption in 
autoinhibition. 
 Figure 5.7: Solvent accessible side chains as a mechanism for autoinhibition. (A) A ribbon diagram shows the D2 domain (D1 
removed for clarity) in the structure of IL-4R (PDB 1IAR). The two Trp side chains in the tryptophan-arginine zipper are shown as red 
spheres. The two arginine side chains in the tryptophan-arginine zipper are shown as grey spheres. (B) Ribbon diagram of the V 
domain in the VC1 x-ray crystal structure. Structure is colored according to % conservation as in Figure 3.4. The side chain atoms are 
shown for Trp61 and Trp72. 
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 Functional Role of the C2 Domain 
 A gap in the knowledge of RAGE structure that is critical to function is the 
relative flexibility of the C2 domain with respect to the membrane. Based on the 
homology model of C2, there is an ~20 residue linker between the end of the C2 
structured region and the start of the transmembrane helix. The flexibility of C2 can be 
tested in vitro by preparing 15N-enriched protein in detergent micelles. An ideal construct 
would contain the C2 domain through the IC. The transmembrane helix would be 
solubilized by the detergent while the IC and the C2 domain would be exposed to solvent. 
 In fact, numerous constructs have been prepared to address this issue and 
preliminary expression and purification suggests sample preparation is feasible. The first 
strategy was to design a construct that would drive expression into the periplasm to 
potentially trap the transmembrane helix in the inner membrane. A second strategy is to 
express protein only with an N-terminal His6 tag. This would eliminate the need to 
separate the fusion from the native protein. In fact, a C2 to IC construct with only a His6 
tag has readily been solubilized in β-octylglucoside, the detergent used in initial RAGE 
isolation (1). 
 NMR linewidths are sensitive to many factors, one being the correlation time of 
the molecule which is proportional to its size. Thus, a solubilized protein would have 
broad lines since the detergent micelle will have a long correlation time due to its size. 
However, regions of a protein that are flexible from the micelle could have shorter 
correlation times and hence narrower linewidths. This property was described in Chapter 
II with the linewidth differences between VC1 and C2 in full sRAGE 15N-1H HSQC 
spectra and equally applies to protein-detergent complexes. 
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  A series of deletions and substitutions have shown that the membrane proximal 
domains of the complex receptor gp130 (containing 6 domains) are essential for efficient 
receptor activation (136). Thus, it is possible that C2 partially embeds in or interacts with 
the membrane and to some degree orients the VC1 region in either an autoinhibited 
conformation or a conformation necessary for activation. If C2 is flexible from the 
transmembrane helix, I anticipate observing signals in a 15N-1H HSQC spectrum that 
correspond to isolated C2. If C2 (or the linker between C2 and the transmembrane helix) 
interacts or embeds with the detergent then perdeuteration and TROSY will be required 
to overcome the broad linewidths caused by the long correlation time. Thus, the relative 
flexibility can be tested by 2D 15N-1H NMR experiments and provide this critical piece of 
information. 
 
Prospects for sRAGE Based Therapeutics 
 Numerous studies described in Chapter I have shown that exogenous sRAGE 
functions as a decoy to block RAGE-ligand signaling in numerous pathologies. This is 
possible due to the absence of an immune response since sRAGE exists in blood plasma 
in an alternatively spliced form (131, 137). Models for advanced atherosclerosis (56), 
tumor growth and metastasis (38, 58), Alzheimer’s disease (60), and chronic 
inflammation (63) have shown exogenous treatment with sRAGE has powerful potential 
for treatment. 
 Due to structural independence of VC1 from C2, in addition to ligand binding 
localization to this region of RAGE, VC1 may provide a more stable alternative to 
working with intact sRAGE. For example, the VC1 construct used in this dissertation has 
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 better solubility properties than the sRAGE construct. Low solubility makes drug 
formulation challenging and can diminish shelf-life. The feasibility of using VC1 as a 
therapeutic should be tested in the mouse models described in Chapter I (using sRAGE 
and isolated C2 as controls) for its potential to augment disease progression. 
 
Closing Remarks 
 Overall, the structural studies reported in this dissertation have provided 
important insight in to the function of RAGE. While many questions have been answered 
with regards to tertiary and quaternary structure, many more need to be answered 
including intact RAGE quaternary structure and the details of ligand recognition. Most 
importantly, this work has established the foundation upon which these future questions 
can be addressed thereby providing a broader understanding of RAGE as a signaling 
receptor in normal physiology and disease. 
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 CHAPTER VI 
 
MATERIALS AND METHODS 
 
Molecular Biology 
 Bacterial expression vectors for RAGE constructs (GenBank accession no. 
NM_001136) were produced by three steps. DNA was extracted from baculovirus-
infected insect cells generously provided by Dr. Ann Marie Schmidt (Columbia 
University, New York, NY) or purchased from Invitrogen. DNA fragments were PCR 
amplified with primers containing the appropriate restriction sites and stop codons. A list 
of constructs including precise sequences, the vector and restriction sites used, and minor 
details of protein expression and purification are shown in Table 6.1. Constructs 
subcloned into the pET15b vector (Novagen) produced N-terminal His6 tagged fusion 
proteins separated by a thrombin cleavage site. Constructs subcloned into pET40b 
produced N-terminal DsbC fusions for periplasmic localization. Creation of a human 
S100B expression vector in pGEMEX, which produced protein of wild-type sequence, 
was described previously (89). Three Cys→Ser mutants of human S100B (C84S, C68S, 
C68S/C84S) were produced in the pGEMEX expression vector using the QuickChange 
strategy (Strategene). 
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 Table 6.1: Summary of expression vectors with expression and purification strategies of 
recombinant proteins. 
 
Protein Vector Sequence Restriction Cell Line Purification║
sRAGE† pET15b   23-327 NdeI/XhoI OrigamiB(DE3) Ni, S
VC1-a† pET15b   23-243 NdeI/XhoI OrigamiB(DE3) Ni, S
VC1-b†§ pET15b   23-233 NdeI/XhoI OrigamiB(DE3) Ni, S
C1C2 pET15b 122-327 NdeI/XhoI OrigamiB(DE3) Ni, S
V-a† pET15b   23-132 NdeI/XhoI OrigamiB(DE3) Ni, S
V-b†§ pET15b   23-119 NdeI/XhoI OrigamiB(DE3) Ni, S
C1-a pET15b 122-243 NdeI/XhoI OrigamiB(DE3) Ni, S
C1-b pET15b 119-233 NdeI/XhoI OrigamiB(DE3) Ni, S
C2 pET15b 235-327 NdeI/XhoI OrigamiB(DE3) Ni, Q
IC-a pET15b 364-404 NdeI/XhoI BL21(DE3) Ni, Q
IC-b pET15b 364-403 NdeI/XhoI BL21(DE3) Ni, Q
RAGE pET15b   23-404 NdeI/XhoI OrigamiB(DE3) Ni
C2IC pET15b 235-404 NdeI/XhoI OrigamiB(DE3) Ni
RAGE pET40b   23-404 NcoI/XhoI BL21(DE3) Ni
RAGE pET40b   23-404 ScaI/XhoI BL21(DE3) Ni
C2IC pET40b 235-404 NcoI/XhoI BL21(DE3) Ni
C2IC pET40b 235-404 ScaI/XhoI BL21(DE3) Ni
TMIC pET40b 364-404 NcoI/XhoI BL21(DE3) Ni
S100B┴ pGEMEX wild-type N/A BL21(DE3) DEAE, S75
 
 
† G82S mutants were prepared for these constructs but were not characterized. 
§ These constructs were prepared by inserting a stop codon after the appropriate sequence 
by the QuickChange mutagenesis strategy. 
║ Symbols used are Ni (Ni2+-affinity), S (MonoS), Q (SourceQ), DEAE (diethyl 
aminoethane), and S75 (Superdex 75). 
┴ C68S, C84S, and C68S/C84S mutants were prepared and purified the same. 
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 Protein Expression and Purification 
 RAGE fragments overexpressed in E. coli strain OrigamiB(DE3) (Novagen) were 
grown at 37 °C to OD600 ~0.8, adjusted to 20 °C for 30 minutes, induced with 0.5 mM 
IPTG, and allowed to express for 4-6 hours. Constructs overexpressed in BL21(DE3) 
were grown the same but lacking the shift to 20 °C. Cells were lysed at 4 °C in 20 mM 
Tris-HCl, 20 mM imidazole, 300 mM NaCl at pH 8.0 in the presence of lysozyme 
(5mg/ml), followed by sonication (5 min with a 50% duty cycle). Clarified lysate was 
initially purified on His-Select (Sigma) resin equilibrated in the lysis buffer and eluted 
with a 4 column volume (CV) linear gradient to 20 mM Tris-HCl, 300 mM imidazole, 
300 mM NaCl at pH 8.0.  Following dialysis, the His6 tag was removed by thrombin 
cleavage (1-2 units per mg of protein) incubated at room temperature for 1-2 hours 
followed by separation over SourceQ (C2) using 20 mM Tris-HCl at pH 7.7 and a 18 CV 
linear gradient from 0 to 1 M NaCl or MonoS (sRAGE, VC1, C1C2, V, C1) using 20 
mM sodium phosphate at pH 6.0 and a 18 CV linear gradient from 150 to 850 mM NaCl 
(GE Healthcare). The His6 tag was not cleaved from C1 or C1C2 due to observation of 
secondary cleavage. The amino acids Gly-Ser-His-Met remained at the N-terminus after 
thrombin cleavage. 
 The expression system for human S100B in pGEMEX vector was described 
previously (89) except luria broth (LB) was used in place of DYT. Cells were 
resuspended in 20 mM Tris-HCl at pH 7.7 and lysed at 4 °C in the presence of lysozyme 
(5mg/ml) followed by sonication (5 min with a 50% duty cycle). Purification of samples 
involved an initial step of DEAE ion exchange chromatography, equilibrated in 20 mM 
Tris-HCl at pH 7.7 and eluting bound protein using a linear gradient from 0 to 1 M NaCl. 
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 This was followed by Superdex 75 gel filtration in 20 mM Tris-HCl, 0.1 mM EDTA at 
pH 7.7. C84S, C68S, and a double C68S/C84S mutant of S100B were purified the same 
as wild-type. 
 Samples of 15N-enriched sRAGE and S100B proteins were produced as described 
above except for the use of M9 minimal media containing 15NH4Cl as the sole nitrogen 
source. 2H,15N-enriched protein (~85% as estimated by MALDI mass spectrometry) was 
produced in a similar manner using cells adapted to growth in 2H2O. The integrity of each 
protein sample was verified by SDS-PAGE and MALDI mass spectrometry. 
 
Limited Proteolysis/Protease Protection 
 Limited proteolysis was performed at room temperature on sRAGE and domain 
fragments that had been dialyzed against 10 mM HEPES-NaOH, 75 mM NaCl at pH 7.0. 
Typically, 50-100 µg of purified protein were incubated with trypsin at an enzyme to 
protein ratio of 1:500 (w/w) and a volume of 100 µl. The reaction was stopped at various 
time points by mixing 14 µl of reaction mix with 14 µl 2x SDS loading buffer and 
heating at 90 °C for 5 minutes. For protection assays, S100B was mixed with sRAGE or 
domain fragments at a 2:1 molar stoichiometry of RAGE to S100B dimer, anticipating 
two binding sites per S100B dimer. CaCl2 was added to a final concentration of 1 mM 
prior to the addition of enzyme. Control experiments with S100B alone and sRAGE or 
domain fragments were performed under identical conditions (i.e. in the presence of 
Ca2+). 
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 Mass Spectrometry 
 Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry 
(MALDI-TOF MS) analysis was performed on tryptic peptides derived from gel-excised 
Coomassie stained bands. Samples were prepared by the dried-droplet method using α-
cyano-4-hydroxycinnamic acid [dissolved in water/acetonitrile/trifluoroacetic acid 
(39.2:60:0.1) at a concentration of 5 mg/mL, supplemented with 1 mg/mL ammonium 
citrate] as a matrix. The peptides were initially identified by comparing the experimental 
masses of each peak with computer-predicted masses of tryptic peptides from the RAGE 
sequence. Amino acid sequence identity was definitively established by inducing ion 
fragmentation using tandem TOF-TOF MS. 
 
Circular Dichroism 
 All samples were buffer exchanged into 50 mM potassium phosphate at pH 7.5. 
Protein concentration was typically around 30 µM. Data ranging from 200-240 nm (1 nm 
increment) were acquired on a Jasco J-810 CD spectrophotometer (Easton, MD). 
Baseline was adjusted during acquisition from data acquired on the solution alone. All 
data were converted to mean residue ellipticity using the following equation: 
[Θ] = 100*signal / C n l 
where [Θ] is mean residue ellipticity in units deg·cm2·dmol-1, signal is the raw signal 
output in mdeg, C is protein concentration in millimolar, n is the number of residues, and 
l is the cell pathlength in centimeters. Fitting using the K2d web server was used to 
estimate secondary structure content (138). 
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  Thermal melts were performed using a scan rate of 60 °C per/h and monitoring β-
sheet ellipticity at 218 nm. Data were acquired in 1 °C increments with a 5 min 
equilibration prior to cooling. 
 
Dynamic Light Scattering 
 All data were acquired using a DynaPro ProteinSolutions molecular sizing 
instrument (Wyatt Technology Corporation). Typically, 150 µM protein in 10 mM 
HEPES-NaOH, 75 mM NaCl at pH 7.0 in a volume of 60 µL were filtered and 
centrifuged at >15,000 x g to remove any particulate matter. Twenty scans were 
accumulated for each sample at room temperature. The data were analyzed using the 
Dynamics 5 software provided by the manufacturer and are represented as mean radius ± 
polydispersity. 
 
Differential Scanning Calorimetry 
 Samples of sRAGE, VC1, C1C2, V, C1, and C2 (50-100 µM) were buffer 
exchanged into 50 mM sodium citrate at pH 6.7 using a 50 mL desalting column (GE 
Healthcare) to ensure identically matched buffer components. Data were collected on a 
VP-DSC (Microcal; Northampton, MA) with a scan from 20 °C to 100 °C at a rate of 90 
°C/hr. 50 mM sodium citrate at pH 6.7 was used as the reference solution. All samples 
and buffers were thoroughly filtered and degassed prior to analysis. Data were analyzed 
using the Origin7 software package provided by the manufacturer, baseline corrected for 
buffer alone, and fit with a non 2-state equation. 
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 Surface Plasmon Resonance 
 CM5 sensor chips, coupling reagents (NHS, EDC and ethanolamine), and P20 
were purchased from Biacore International SA (Freiburg, Germany).  CM5 sensor chips 
were preactivated using the NHS:EDC chemistry according to previously published 
procedures (139, 140). 50 µg/ml V, VC1, C2, or yeast sRAGE in sodium acetate buffer at 
pH 5.5 was injected over the preactivated surface in order to obtain about 5000 RU. The 
surface was then blocked with ethanolamine. In each experiment, the fourth flow-cell of 
the sensor chip was kept empty and used as an internal reference. A series of various 
concentrations, ranging from 12.6 µM to 1.57 µM for S100B, were injected over the 
flow-cells. The running buffer was 50 mM Tris-HCl, 150 mM NaCl, 5 mM CaCl2, 
0.005% P20 at pH 7.4. The surface was regenerated each time by 1 min contact with 0.5 
M EDTA following by 1 min contact with 50 mM borate, 1M NaCl at pH 8.5. 
 Binding data were analyzed by global analysis using BiaEvaluation 3.1 software 
from the manufacturer (Biacore), in which association and dissociation data for the series 
of S100B concentrations were fitted simultaneously (141). 
 
Nuclear Magnetic Resonance Spectroscopy 
 Standard 15N-1H HSQC and TROSY-HSQC (111) spectra were acquired at 298 K 
on Bruker Avance 600 and 800 MHz spectrometers equipped with triple resonance 
cryoprobes. Typical acquisition parameters were 128 scans with 1024 points in the direct 
(1H) dimension and 128 points in the indirect (15N) dimension. Fourier transform, zero 
filling, and a 90 degree shifted squared sine window function were applied using 
XWINNMR (Bruker) and analyzed using Xeasy (142). The spectrum for sRAGE was 
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 obtained in a solution containing 200 µM protein in 20 mM sodium phosphate, 250 mM 
NaCl at pH 6.0. Initial spectra for the other constructs were obtained under these 
conditions, and then optimized specifically for each. Deviations from the sRAGE 
conditions were: V, 10 mM sodium citrate at pH 6.0; C2, 20 mM sodium phosphate at pH 
6.0. Protein concentrations were determined using the UV absorbance at 280 nm under 
denaturing and reducing conditions and ranged from 200 to 500 µM. 
 For studying sRAGE-S100B interactions, 15N-V and unlabeled S100 proteins 
were buffered in 10 mM HEPES-NaOH at pH 7.0, 75 mM NaCl and 10 mM CaCl2. 
Spectra of isolated proteins and protein-protein complexes were acquired under identical 
conditions with a 2:1 ratio of RAGE to S100B dimer. Samples of 2H,15N-sRAGE were 
buffer exchanged into 20 mM sodium phosphate and 500 mM NaCl at pH 6.0 in 100% 
H2O. Sample volume was ~160 µL in a 3 mm NMR tube, which was placed within a 5 
mm NMR tube filled with >99.9% 2H2O. 
 Sequence-specific backbone assignments for C2 were made using 600 µM 
15N,13C-enriched protein using standard triple-resonance experiments. This included the 
following 3D spectra: HNCA, HN(CO)CA, HNCO, HNCACB, CBCA(CO)NH. Typical 
acquisition parameters included 2048 points in the direct dimension (1H) with 40 (15N) 
and 96 (13C) increments in the indirect dimensions. Deviations included 128 and 64 
increments (13C) for HNCACB and HNCO, respectively. 
 
Homology Modeling and Structure Analysis 
 Sequences for human sRAGE and domain constructs were submitted to the 
ESyPred3D web server (143). The program performs all steps of homology modeling 
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 including homolog identification (PSI-BLAST of NCBI NR databank then scored against 
the PDB), multiple sequence and pairwise alignments (combination of ClustalW, 
Dialign2, Match-Box, Multalin, and PRRP), and model building (MODELLER). Models 
were generated using the following proteins: VC1, Fab light chain in complex with 
human factor 8 (PDB 1IQD); V, mouse junction adhesion molecule (PDB 1F97); C1, 
human B7-1 (PDB 1DR9); C2, human APEP-1 (PDB 1U2H). Side chains were repacked 
and energy minimized using SCWRL 3.0 (144).  PROCHECK was used to assess the 
stereochemical properties of each model (145). To analyze the surface area buried in the 
V-C1 contacts, the model was split after the linker. Fast Connolly surfaces were 
generated in the program Sybyl (Tripos). Surfaces for the homology model included VC1 
(25-222), V domain (25-121), and C1 domain (122-222). Surfaces for the x-ray crystal 
structure included VC1 (22-233), V domain (22-118) and C1 domain (119-233). Residue 
specific solvent accessible surface area was calculated with Naccess. 
 
CML Synthesis 
 
Synthesis of N(alpha)-Boc-N(epsilon)-(carboxymethyl)lysine 
 The following syntheses were performed by Dr. Guenter Fritz at the University of 
Konstanz. N(alpha)-tert-Boc-L-lysine (Figure 6.1A) (985 mg, 4 mmol) and sodium 
glyoxylate (Figure 6.1B) (684 mg, 6 mmol) were dissolved  in 8 ml 0.5 M sodium citrate. 
The solution was adjusted to pH 6 with 1M NaOH and stirred for 1 h at 65 °C. 
Subsequently, NaCNBH3 (384 mg, 6.12 mmol) was added and the solution was stirred 
continuously for 12.5 h at 65 °C. Samples were taken regularly and analyzed using thin 
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 layer chromatography (TLC). After 14 h of reaction time TLC analysis could not detect 
any remaining N(alpha)-tert-Boc-L-lysine in the solution. After completion of the 
reaction, the solution was concentrated in a rotary evaporator. The remaining solution 
was dissolved in methanol and desalted using a short column packed with cellulose. After 
washing with additional methanol, the collected filtered solution was dried. In a second 
desalting step, the residue was dissolved in methanol and separated through a long 
column packed with cellulose. Yield is 1086 mg (3.56 mmol, 88.9%). 
 
Synthesis of N(epsilon)-(carboxymethyl)-lysine 
 N(alpha)-Boc-N(epsilon)-(carboxymethyl)lysine (Figure 6.1D) (1086 mg, 3.56 
mmol) was dissolved in 10 ml of 3 M HCl and heated for 1 h at 70 °C. After removal of 
HCl in a vacuum concentrator, the residue was re-crystallized in water ethanol. Yield is 
5,728 mg (2.62 mmol; 73.79%). 
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COOH 
Figure 6.1: Reaction scheme for synthesis of N(epsilon)-(carboxymethyl)lysine. 
Synthesis steps are described in the text. 
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APPENDIX A 
 
MULTIPLE SEQUENCE ALIGNMENT OF SRAGE PROTEINS 
 
 Figure A.1 shows the full sequence alignment of sRAGE proteins from human, 
bovine, rat, and mouse. Sequences for human (Q15109), bovine (Q28173), rat 
(Q63495) and mouse (Q62151) sRAGE were aligned using ClustalX run on a Windows 
PC. This is the alignment for which discussion in this dissertation are based. 
Figure A.1: Multiple sequence alignment of sRAGE from four species. The numbering corresponds to the human sequence. The 
residues implicated in the strand g bulge as described in Chapter III are contained within red boxes. Position 227 which may 
contribute to strand g swapping as described in Chapter III is contained within a green box. Residues implicated in the V-C1 linker as 
described in Chapter III are contained within blue boxes. Tryptophan residues discussed in Chapter IV are contained within violet 
boxes. 
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 APPENDIX B 
 
SUMMARY OF CRYSTALLIZATION STATISTICS FOR VC1 
 
 The following tables for statistics on the crystal structure of VC1 were provided 
by Dr. Guenter Fritz from the University of Konstanz. 
 
Table B.1: Statistics of data collection and Zn MAD phasing. 
Data set Peak Inflection Remote High
Wavelength (Å) 1.282 1.283 1.008
Resolution limits (Å) 30-2.0 (2.1-2.0) 30-2.0 (2.1-2.0) 30-2.0 (2.1-2.0)
Unique reflections 33711 (4577) 33708 (4581) 33660 (4588)
Redundancy 3.7 (3.3) 3.7 (3.3) 3.8 (3.7)
Completeness (%) 99.9 (99.7) 99.9 (99.8) 99.7 (100.0)
I/σ 9.4 (2.1) 9.7 (2.2) 10.7 (3.8)
Rsym (%) 9.2 (55.5) 8.4 (51.5) 7.7 (31.9)
Rmeas (%) 10.4 (64.8) 9.8 (61.4) 8.9 (37.3)
B-factor (Wilson plot) 35.1 35.1 33.2
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 Table B.2:  Statistics for highest resolution dataset. 
Resolution limits (Å) 30-2.0  (2.0-1.8)
Wavelength (Å) 1.008
Reflections 174312  (47326)    
Unique reflections  24993  (6640)
Completeness (%) 99.7  (99.9)
I/σ   11.2  (2.8)
Rmerge (%) 9.7  (43.9)
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 APPENDIX C 
 
15N-1H HSQC SPECTRA OF OPTIMIZED SRAGE CONSTRUCTS 
 
 The initial sRAGE constructs used in Chapters II, III, and IV were designed based 
on a combination of multiple sequence alignments and secondary structure prediction as 
described in Chapter II. 15N-1H HSQC spectra of both VC1 and V revealed ~10 
resonances with very sharp linewidths consistent with high flexibility. The x-ray crystal 
structure presented in Chapter III confirmed the existence of highly flexible C-terminal 
extensions. Based on analysis of the x-ray crystal structure, optimized VC1, V, and C1 
constructs were designed and are listed in Table 6.1 as VC1-b, V-b, and C1-b. Overall, 
both the VC1 and V constructs behaved exactly as the originals through all steps of 
purification. The 15N-1H HSQC spectra of the new VC1 (Figure C.1) and V (Figure C.2) 
constructs show these are valid reagents for further structural and macromolecular 
interaction studies. The C1 construct showed lower expression and its 15N-1H HSQC 
spectrum was characteristic of a completely unfolded protein. However, the His6 tag had 
been removed by thrombin cleavage. Previous work on the original C1 construct (122-
243) revealed significant secondary cleavage during thrombin incubation. While 
preliminary work on the new C1 construct (119-233) suggested it was stable to secondary 
cleavage, the final NMR sample showed signs of degradation. Thus, these data should be 
reacquired with this issue in mind. Lastly, Figure C.4 compares the new VC1 and V 
constructs showing significant chemical shift perturbations, confirming the structural 
interface described in Chapters II and III. 
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Figure C.1: 15N-1H HSQC spectra of VC1(23-233). Data were collected at 600 MHz and 
298K in 30 mM potassium phosphate at pH 6.0. 
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Figure C.2: 15N-1H HSQC spectra of V(23-119). Data were collected at 600 MHz and 
298K in 30 mM potassium phosphate at pH 6.0. 
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Figure C.3: 15N-1H HSQC spectra of C1(119-233). Data were collected at 600 MHz and 
298K in 30 mM potassium phosphate at pH 6.0. 
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Figure C.4: Optimized V shows structural changes in the context of VC1. Overlay of 
15N-1H HSQC spectra of V(23-119) in red and VC1(23-233) in black. The same peaks 
perturbed in Figure 2.11 are perturbed in this analysis. 
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 APPENDIX D 
 
TABLE OF BACKBONE ATOM CHEMICAL SHIFTS FOR C2 
 
Table D.1: 1H, 15N, 13C backbone chemical shifts for C2. 
Res Num N NH CA CB
E236 53.85 27.92
E237 120.97 8.19 55.03 28.60
V238 118.74 7.75 59.40 30.74
Q239 126.22 9.01 52.17 28.90
L240 125.34 8.58 51.74 42.21
V241 128.63 9.23 59.18 31.79
V242 125.59 8.47 57.47 32.56
E243 126.59 8.44 50.21 30.63
P244 60.37 32.07
E245 121.28 8.65 56.35 27.24
G246 110.49 8.64 43.01
G247 106.98 8.19 44.02
A248 120.36 7.28 47.90 17.52
V249 118.23 8.30 56.58 33.98
A250 126.03 8.15 48.13 14.82
P251 61.57 28.76
G252 112.57 9.07 43.06
G253 108.95 8.30 42.17
T254 113.29 7.90 58.90 69.24
V255 126.22 8.12 57.81 32.67
T256 121.46 8.75 59.74 67.97
L257 129.55 9.13 51.79 41.40
T258 116.94 8.99 59.48 68.38
C259 127.76 9.35 52.63 43.25
E260 124.67 9.04 53.04 29.87
V261 123.13 8.64 55.90
P262 62.20 29.60
A263 118.10 8.43 50.63 16.47
Q264 117.27 7.66 27.96
P265
S266  
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 Table D.1: continued 
Res Num N NH CA CB
P267 60.42 29.84
Q268 121.27 8.67 53.04 27.00
I269 126.58 8.23 56.52 36.59
H270 120.81 8.55 51.62 29.50
W271 120.96 8.77 55.29 30.73
M272 120.98 9.20 51.21 33.05
K273 119.72 8.57 51.97 33.72
D274 128.19 9.87 53.21 37.33
G275 101.03 8.12 42.88
V276 121.14 7.78 56.43 32.30
P277
L278
P279
L280
P281
P282
S283
P284 62.05 29.96
V285 115.02 7.53 57.39 33.19
L286 131.09 9.05 51.37 39.37
I287 125.93 8.13 57.69 37.26
L288 128.46 8.84 48.29 39.18
P289 59.89 30.16
E290 118.30 7.77 53.14 26.28
I291 119.79 8.47 60.51 35.99
G292 114.12 8.92 41.52
P293 63.12 29.41
Q294 115.52 9.07 55.21 24.97
D295 116.83 8.15 52.91 40.51
Q296 117.75 7.23 54.93 28.59  
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 Table D.1: continued 
Res Num N NH CA CB
G297 108.65 8.16 42.63
T298 116.06 8.85 58.84 67.34
Y299 127.02 9.52 54.63 40.56
S300 111.07 8.75 54.78 63.15
C301 114.10 8.58 50.53 45.37
V302 118.92 8.52 57.74 32.40
A303 128.73 8.90 47.59 19.22
T304 115.29 8.47 59.60 67.57
H305 121.48 8.47
S306
S307
H308 52.71 27.41
G309 108.36 8.09 42.27
P310
Q311
E312 52.07 29.98
S313 120.60 8.96 56.25 64.36
R314 116.74 8.51 53.85 27.50
A315 124.39 8.32 48.12 18.12
V316 119.01 9.13 57.63 32.55
S317 120.45 8.53 55.40 61.24
I318 127.23 9.05 55.79 35.02
S319 122.14 8.73 54.13 63.98
I320 119.33 8.08 56.56 36.62
I321 126.96 8.19 57.96 37.01
E322 126.67 8.37 51.61 27.27
P323 60.99 29.76
G324 109.11 8.40 42.60
E325 120.10 8.24 54.03 27.93
E326 121.31 8.48 54.22 27.94
G327 115.64 7.93 43.71  
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